Target molecule-cell complex and preparation method thereof

Abstract

A target molecule-cell complex useful in the treatment and / or prevention of cancer, and a method for preparing the same. The target molecule-cell complex is a complex having the formula (I) 'X-A1-L-A2-D', wherein: X is a cell; a < 1 > is a substituted or unsubstituted indazolone moiety (indazolone moify), and B < 1 > is a substituted or unsubstituted indazolone moiety; l is-O-(CH2) m-W-(CH2) n-, where m and n are each independently an integer between 0 and 10, W is a single bond or-NHCO-or a substituted or unsubstituted polyethylene glycol (poly (ethylene glycol), PEG) of 1 to 4 units; a2 is-CONH <-> or-COS <->; and D is a target motify, and D is a target motify.

Description

Target molecule-cell complex and preparation method thereof Technical Field The present invention relates to the treatment and / or prevention of cancer, and in particular to a target molecule-cell complex containing a specific linker and a preparation method thereof. Background Art In recent years, cell therapy technology has made great progress in the field of cancer treatment. Among them, traditional cell therapy that injects autologous or allogeneic natural killer cells (NK cells) or T cells into cancer patients can show a certain degree of efficacy for the human body, but the role and efficacy of the cells are limited by the molecules presented on their surface. Taking traditional non-genetically modified T cells as an example, these T cells are limited to responding to tumor antigen peptides presented by the major histocompatibility complex (MHC), but the major histocompatibility complex of cancer cells is low, which limits the therapeutic effect. In this regard, existing technologies use synthetic chimeric antigen receptors (CARs) to bypass the restrictions of MHC, thereby directly acting on target molecules on the surface of malignant cells with specific cytotoxicity. Among them, chimeric antigen receptor T cell therapy (CAR-T cell therapy; CAR-T cell therapy) for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma (such as: ), has successfully demonstrated the potential of immune cells in the development of cancer immunotherapy. However, the manufacturing process of CAR-T cells is still technically difficult, expensive and time-consuming, and there are safety concerns such as virus residues. In summary, in the treatment or prevention of cancer, the existing technology is not satisfactory in all aspects, and there is a need for further improvement. Summary of the invention In view of this, the present invention provides a cross-linked complex molecule and a cross-linking method, which has a photoreactive functional group portion and a target molecule bonding portion (targeting molecule moeity), and the photoreactive functional group portion can be irradiated with ultraviolet light (UV) to bind to the amino functional group (-NH2) on the cell surface protein. The cross-linked complex molecule provided by the present invention can also be irradiated with ultraviolet light to bind to the amino functional group (-NH2) on the cell surface protein when it is bonded to the target molecule (targeting molecule). The invention provides a faster and less expensive cell therapy drug and a method for producing the same. Based on the above, the present invention mainly provides a target molecule-cell complex for the treatment and / or prevention of cancer, which comprises the following [1]~

[0013] Any composition of: [1] A target molecule-cell complex having formula (I): X-A1-L-A2-D formula (I) in: X is a cell; A1 is a substituted or unsubstituted indazolone moiety; L is -O-(CH2) m -W-(CH2) n -, wherein m and n are each independently an integer between 0 and 10, and W is a single bond or -NHCO- or a substituted or unsubstituted 1-4 unit polyethylene glycol (PEG); A2 is -CONH- or -COS-; and D is a targeting moiety. [2] The target molecule-cell complex as described in [1], wherein A1 is an indazolone group substituted with a methoxy group. [3] The target molecule-cell complex described in [2] has a structure of formula (II) or (III): where X, L, A2 and D are defined as in [1]. [4] The target molecule-cell complex as described in [1], wherein L is -O-(CH2) m+n -, and 3≦(m+n)≦9. [5] The target molecule-cell complex as described in [1], wherein L is -O-(CH2) m -NHCO-(CH2) n -, and 3≦(m+n)≦9. [6] The target molecule-cell complex as described in [1], wherein L is 1-4 units of substituted or unsubstituted polyethylene glycol. [7] The target molecule-cell complex as described in [1], wherein the cell is a mesenchymal stem cell, A blood cell or a bacterial cell. [8] The targeting molecule-cell complex as described in [7], wherein the mesenchymal stem cells include adipose-derived mesenchymal stem cells (ADMSC), hematopoietic stem cells, bone marrow mesenchymal stem cells, umbilical cord mesenchymal stem cells and placental stem cells. [9] The target molecule-cell complex as described in [7], wherein the blood cell comprises a platelet, a T cell (T lymphocyte), a natural killer cell (NK cell), a super natural killer cell (Snk cell), a cytokine-activated killer cell (CIK cell), a dendritic cell, a macrophage, a granulocyte or a combination thereof.

[0010] The target molecule-cell complex as described in [1], wherein the target portion is an antigen-binding molecule.

[0011] The target molecule-cell complex as described in

[0010] , wherein the target portion has an amine group (NH2 group) or a sulfhydryl group (sulfhydryl group).

[0012] The target molecule-cell complex as described in

[0010] , wherein the target moiety is a small molecule, an aptamer, a peptide, an antibody or a combination thereof.

[0013] The target molecule-cell complex as described in

[0011] , wherein the antibody is a single-chain variable fragment (scFv), a fragment antigen binding (Fab) fragment or a full-length antibody. In addition, the present invention also provides a method for preparing a target molecule-cell complex, which comprises any one of the following compositions

[0014] to

[0023] :

[0014] A method for preparing a target molecule-cell complex comprises: A connector having the formula (IV) is provided: Wherein, L is -O-(CH2)m -W-(CH2) n -, wherein m and n are each independently an integer between 0 and 10, and W is a single bond or -NHCO- or a substituted or unsubstituted polyethylene glycol of 1 to 4 units; The linker is reacted with a target molecule having an amine group to form a linker-target molecule complex. A compound, wherein the linker is bound to the target molecule via an amide bond; and The linker-target molecule complex is irradiated with ultraviolet light to make the linker-target molecule complex after irradiation with ultraviolet light react with a cell, wherein the linker-target molecule complex and the cell form a target molecule-cell complex through an indazolone part.

[0015] The method for preparing a target molecule-cell complex as described in

[0014] , wherein the connector has a structure selected from the group consisting of the following compounds: as well as

[0016] The method for preparing a target molecule-cell complex as described in

[0014] , wherein the molar ratio of the target molecule to the connector used to form the connector-target molecule complex is 1:1 to 1:15.

[0017] The method for preparing the target molecule-cell complex as described in

[0014] , wherein the step of irradiating the linker-target molecule complex with ultraviolet light is performed in a cycle of irradiating the linker-target molecule complex with ultraviolet light for 5 to 30 seconds and letting it stand for 1 to 30 seconds.

[0018] The method for preparing a target molecule-cell complex as described in

[0014] , wherein the cycle is performed 1 to 6 times.

[0019] The method for preparing the target molecule-cell complex as described in

[0014] , wherein the step of allowing the linker-target molecule complex irradiated with ultraviolet light to react with the cell is carried out for at least 1 minute.

[0020] In the method for preparing the target molecule-cell complex as described in

[0014] , the step of irradiating the connector-target molecule complex with ultraviolet light comprises first mixing the connector-target molecule complex with the cell, and then irradiating the connector-target molecule complex and the cell simultaneously with ultraviolet light.

[0021] A use of the target molecule-cell complex described in [1] in the preparation of a drug for treating cancer.

[0022] A target molecule-cell complex as described in [1] is used in the preparation of a cell homing promoter (homing) The purpose of the drug.

[0023] A use of the target molecule-cell complex as described in [1] in the preparation of a drug for treating autoimmune diseases. Through the above-mentioned structure, the cross-linked complex molecule of the present invention can prepare a target molecule-cell complex in a non-genetic modification manner through the photoreactive functional group part and the target molecule bonding part. Therefore, the cross-linked complex molecule of the present invention has at least the following advantages: (1) It is a small molecule and therefore cheap to produce; (2) The photoreactive functional group combines very quickly with the amino functional group (-NH2) on the cell (the reaction time is about 1-10 minutes), so its production process is fast and simple; (3) No viral vector that can insert human genes is used, so the quality control cost and safety concerns caused by residual viruses in the process can be reduced; (4) It can be widely combined with the amino functional group (-NH2) on different cells; (5) Through the cross-linked complex molecule-target molecule binding to the cell, the cell efficacy is enhanced, such as enhancing cell toxicity and inhibiting tumor growth; (6) The cross-linked complex molecule of the present invention has better cell binding ability and cell efficacy than other connectors. In summary, by using the cross-linked complex molecules of the present invention, a target molecule-cell complex that can be effectively used in the treatment and / or prevention of cancer and a method for preparing the target molecule-cell complex can be provided. BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a flow chart showing the preparation of linker formula α. FIG. 2 is a nuclear magnetic resonance (NMR) analysis spectrum showing the connector chemical formula α. FIG. 3 is a liquid chromatography-tandem mass spectrometry (LC-MS / MS) analysis spectrum showing the connector chemical formula α. FIG. 4 is a flow chart showing the preparation of linker formula β. FIG. 5 is an NMR analysis spectrum showing the connector chemical formula β. FIG. 6 is a LC-MS / MS analysis spectrum showing the connector chemical formula β. FIG. 7 is a flow chart showing the preparation of linker formula γ. FIG. 8 is an NMR analysis spectrum showing the connector chemical formula γ. FIG. 9 is a LC-MS / MS analysis chart showing the connector chemical formula γ. FIG. 10 is a flow chart showing the preparation of linker formula δ. FIG. 11 is an NMR analysis spectrum showing the connector chemical formula δ. FIG. 12 is a LC-MS / MS analysis spectrum showing the connector chemical formula δ. FIG. 13 is a graph showing the results of sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of trastuzumab conjugated with different hydrocarbon chain linkers. FIG. 14 is a graph showing the results of a comparative test of the extent of binding of trastuzumab bound with different hydrocarbon chain linkers to ADMSCs. FIG. 15 is a graph showing the results of a comparative test of the degree of binding of trastuzumab bound with different hydrocarbon chain linkers to NK cells. FIG. 16 is a graph showing the effect of trastuzumab-NK cells bonded with different hydrocarbon chain linkers on the cytotoxicity of solid tumor breast cancer cells. FIG. 17 is a graph showing the results of the degree of binding of trastuzumab bound with different linkers to NK. 18A-18C are graphs showing the apoptosis of three solid tumor cancer cells caused by NK cell cytotoxicity of trastuzumab bound with different linkers. FIG. 19 is a graph showing the results of different binding reaction times of linker-bound trastuzumab to NK cells. FIG. 20 is a graph showing the extent to which linker-bound trastuzumab is bound to the surface of NK cells at different times. FIG. 21 is a graph showing the results of the binding reaction of trastuzumab bonded with the linker chemical formula α to platelets. FIG. 22 is a diagram showing the chemical formula of the linker α-bonded trastuzumab to CD41 + Diagram of the bonding ability of platelets. FIG. 23 is a diagram showing the binding of trastuzumab to CD3 + / CD8 + Diagram of the results of the T cell binding reaction. FIG. 24 is a diagram showing the effect of the linker chemical formula α on the binding of trastuzumab to CD3 + / CD8 + Diagram of the binding capacity of T cells. FIG. 25 is a diagram showing the linker-bound trastuzumab-CD16 +A graph showing the degree of bonding of NK cell membranes at different times. FIG. 26 is a diagram showing the linker-bound trastuzumab bound to CD16 + Graph showing the results of cell viability 96 hours after NK. FIG. 27 shows the results of the binding of Rituximab to NK cells with a linker . FIG. 28 is a graph showing the binding ability of linker-bound rituximab to NK cells. FIG. 29 is a diagram showing the results of the binding of linker-bound atezolizumab to NK cells. FIG. 30 is a graph showing the binding ability of linker-bound Atezolizumab to NK cells. FIG31 is a graph showing the results of a rituximab-bound PBMC cytotoxicity assay. FIG. 32 is a graph showing the results of BT474 tumor volume measurements. FIG. 33 is a graph showing the results of BT474 tumor growth inhibition (TGI) analysis. FIG. 34 is a graph showing the results of analysis of linker-bound trastuzumab-NK cell cytotoxicity against N87 gastric cancer cells. FIG. 35 is a graph showing the results of analysis of the cytotoxicity of H2170 lung cancer cells by linker-bound trastuzumab-NK cells. FIG. 36 is a graph showing the results of analyzing the degree of binding of trastuzumab bound to NK cells with different linkers at different UV irradiation energies. FIG37 is a graph showing the results of analysis of the degree of binding of trastuzumab bound with different linkers to NK cells at different reaction times after UV irradiation. FIG. 38 is a graph showing the analysis of the extent of NK binding of trastuzumab with different linkers at different antibody concentrations. FIG. 39 is a graph showing the analysis of the cell cytotoxicity results of trastuzumab bound with different linkers at different antibody concentrations. DETAILED DESCRIPTION [Modes for carrying out the invention] The following is a description of the embodiments of the present invention. However, the present invention is not limited to the following embodiments. The therapeutic or preventive drugs and therapeutic or preventive methods of the present invention can be administered or applied to humans. In this specification, "~" and "-" indicating a range include the values ​​of the end points. For example, "A~B" and "AB" mean a range above A and below B. In the present invention, the meaning of the term "and / or" includes appropriate combinations of "and" and "or". Specifically, "A, B, and / or C" includes the following 7 variations: (i) A, (ii) B, (iii) C, (iv) A and B, (v) A and C, (vi) B and C, (vii) A, B, and C. In the present invention, the term "about" is used to refer to a value and includes the standard deviation of the error of the device or method used to determine the value. In certain embodiments, unless otherwise specified or obvious from the context (for example, when the value exceeds 100% of the possible value), the term "about" refers to a range of values ​​that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less of the stated value in any direction (greater than or less than). One embodiment of the present invention is a cross-linked complex molecule having a structure represented by the following formula (A). Wherein, L is -O-(CH2) m -W-(CH2) n -, m and n are each independently an integer between 0 and 10, W is a single bond or -NHCO- or substituted or unsubstituted polyethylene glycol (PEG). In some embodiments, W is 1-4 units of polyethylene glycol. Specifically, the cross-linked complex molecule may include a photoreactive functional group portion represented by the following manner (A-1), and a target molecule bonding portion represented by the following manner (A-2), and the two portions are connected by L. In some embodiments, the cross-linked complex molecules of the present invention are preferably formed by bonding N-hydroxysuccinimide ester and 4-((4-hydroxymethyl)-2-methoxy-5-nitrophenoxy)butanoic acid. In some embodiments, the benzene ring of the photoreactive functional group portion (A-1) of the cross-linked complex molecule The hydrogen on the alkyl group may be further replaced by other optional substituents. The above other optional substituents may be, for example, halogen, hydroxyl, thiol, amine, nitro, cyano, aldehyde, ketone, ester, amide, phosphonic acid, phosphonate, sulfonic acid, sulfonate, sulfone, sulfoxide, aryl, heteroaryl, alkyl, alkoxy, alkylene or modified alkyl, but the present invention is not limited thereto. In some embodiments, the above other optional substituents are methoxy. The cross-linked complex molecules of the present invention can be subjected to photochemical cyclization by irradiating the photoreactive functional group portion (A-1) with ultraviolet light (UV), so that it can be combined with an amino functional group (-NH2) on the surface of a cell to form an indazolone moiety. In some embodiments, the wavelength of the ultraviolet light used for the photochemical cyclization reaction can be 300-400 nanometers, for example, ultraviolet light in the UVA band with a wavelength between 320-400 nanometers. The present invention is not particularly limited as long as the cell that binds to the cross-linked complex molecule of the present invention has an amine functional group (-NH2) on its surface that can react with the photoreactive functional group part (A-1) to form an indazolone part. Examples of such cells include: mesenchymal stem cells, blood cells or bacterial cells. The above-mentioned mesenchymal stem cells may include: adipose-derived mesenchymal stem cells, hematopoietic stem cells, bone marrow mesenchymal stem cells, umbilical cord mesenchymal stem cells and placental stem cells, or a combination thereof. The above-mentioned blood cells may include: platelets, T cells, natural killer cells, dendritic cells, macrophages, granulocytes, or a combination thereof. On the other hand, the target molecule bonding part (A-2) of the cross-linked complex molecule of the present invention can first react with the target molecule through the N-hydroxysuccinimide part, so that it is bonded to the target molecule through an amide bond (conjugate) to form a connector-target molecule complex. Then, the connector-target molecule complex can be further irradiated with ultraviolet light to cause the photochemical cyclization reaction of the photoreactive functional group to bind to the cell, thereby forming a target molecule-cell complex. In some embodiments, the molar ratio of the target molecule to the connector in the connector-target molecule complex is 1:1 to 1:15. In some embodiments, ultraviolet light irradiation is performed in a cycle of irradiation for 5 to 30 seconds and then standing for 1 to 30 seconds. In some embodiments, the aforementioned cycle can be performed 1 to 6 times. In some embodiments, after ultraviolet light irradiation, the connector-cell complex can be allowed to react with the cell for at least 1 minute. It should be noted that the present invention does not specifically limit the order in which the cross-linked complex molecules bind to cells and target molecules, so the cross-linked complex molecules can first bind to cells to form a linker-cell complex and then bind to the target molecule to form a target molecule-cell complex. The following (I) shows an example of a target molecule-cell complex: X-A1-L-A2-D formula (I) Wherein, X is a cell; A1 is a substituted or unsubstituted indazolone moiety; L is -O-(CH2) m -W-(CH2) n -, wherein m and n are each independently an integer between 0 and 10, W is a single bond or -NHCO- or a substituted or unsubstituted polyethylene glycol of 1 to 4 units; A2 is -CONH- or -COS-; and D is a targeting moiety. Formula (II) and Formula (III) further show other examples of target molecule-cell complexes. As can be seen from Formula (II) and Formula (III), the photoreactive functional group portion of the cross-linked complex molecule is combined with cell X to form an indazolone portion, and the target portion A2 is bonded to the target molecule D. Wherein, L is -O-(CH2) m -W-(CH2) n -, m and n are each independently an integer between 0 and 10, W is a single bond or -NHCO- or substituted or unsubstituted polyethylene glycol (PEG); A2 is -CONH- or -COS-; and D is a targeting moiety. In some embodiments, W is 1-4 units of polyethylene glycol. In the present invention, the term "targeting molecule" refers to a specific molecule that has anti-tumor efficacy and specifically inhibits tumors, and the target molecule can form a linker-target molecule complex with the cross-linked complex molecule of the present invention, or further form a target molecule-cell complex. On the other hand, the term "targeting moiety" refers to a part derived from a target molecule in a linker-target molecule complex or a target molecule-cell complex. The above-mentioned target molecules include, but are not limited to: antibodies, proteins, peptides, small molecules, nucleic acid molecules, and they can be obtained from commercially available suppliers or manufactured according to known methods. Examples of target molecules include: antibodies such as Cetuximab, Bevacizumab, Panitumumab, Trastuzumab, Atezolizumab, Rituximab, Tositumomab, Ibritumomab, Alemtuzumab, Eprtuzumab, and Natalizumab; small molecule drugs such as Gefitinib, Erlotinib, and Afatinib; aromatic amide derivatives with anti-tumor activity, etc. In some embodiments, the target molecule / moiety may be an antigen-binding molecule. In some embodiments, the target molecule / moiety may be an antigen-binding molecule. The target moiety may be a small molecule, an aptamer, a peptide, an antibody, or a combination thereof. In some embodiments, the target molecule may be trastuzumab, atezolizumab, or rituximab. In some embodiments, the antibody may be a single chain variable fragment (scFv), a fragment antigen binding (Fab) fragment, or a full-length antibody. In some embodiments, the target moiety may have an amine group (NH2 group) or a sulfhydryl group (sulfhydryl group). The target molecule-cell complex of the present invention can be used for the treatment and prevention of cancer, and can also be used to treat autoimmune diseases. In some embodiments, the target molecule-cell complex can be used to promote cell homing. In the present invention, the term "cancer treatment" refers to reducing the number of cancer cells in an individual, inhibiting the proliferation of cancer cells, reducing tumor volume, reducing tumor weight, inhibiting the metastasis of cancer cells, or improving various symptoms caused by cancer. In addition, the term "cancer prevention" refers to preventing the increase in the number of cancer cells caused by the re-proliferation of reduced cancer cells, preventing the re-proliferation of cancer cells whose proliferation is inhibited, and preventing the volume or weight of reduced tumors from increasing again. In the present invention, the term "cancer" includes solid cancers and blood tumors, and no matter what type, they are composed of cells with uncontrolled abnormal proliferation. Solid cancers are formed by one or more tumors, while blood tumors circulate throughout the body through the blood flow. In the present invention, the so-called "target molecule-cell complex for treating and / or preventing cancer" refers to a target molecule-cell complex that can be used to treat and / or prevent cancers such as solid cancers and / or blood tumors. In the present invention, the above-mentioned cancers can be exemplified as lung cancer, esophageal cancer, gastric cancer, colon cancer, uterine cancer, ovarian cancer, ampullary cancer, pancreatic cancer, pancreatic cancer, bladder cancer, thyroid cancer, skin cancer, head and neck cancer, liver cancer, breast cancer, colon cancer, kidney cancer, muscle tumor, prostate cancer, testicular cancer, bile duct cancer, Merkel cell carcinoma, schwannoma, adrenal cancer, anal cancer, central nervous system tumor, neuroendocrine tissue tumor, penile cancer, pleural tumor, salivary gland tumor, vulvar cancer, thymoma, childhood cancer (such as Wilms tumor, neuroblastoma, sarcoma, hepatoblastoma, germ cell tumor), leukemia, malignant lymphoma, multiple myeloma, etc., but the present invention is not limited thereto. In some embodiments, the cancer is breast cancer, colon cancer, pancreatic cancer, lung cancer, gastric cancer. [Example] The following will further illustrate the specific content of the present invention through a number of examples, but the present invention is not limited to these examples. The materials, agents, etc. used in each example can be obtained from commercially available suppliers, or synthesized using known methods. Example 1 [Preparation method of linker formula α] FIG1 shows the preparation process of the connector chemical formula α shown below. The detailed synthesis steps of the connector chemical formula α will be described below with reference to FIG. 1 . Step 1: 20 g, 0.13 mol of 4-hydroxy-3-methoxybenzaldehyde (Compound 1) was dissolved in 150 mL of dimethylformamide (DMF), and then 27.4 g, 0.2 mol of K2CO3 and 25 g, 0.14 mol of methyl 4-bromobutanoate were added, and stirred at room temperature for 14 hours. Then, water was added to the resulting mixture at 0°C, and the resulting solid was filtered to obtain 30 g, 90% of Compound 2 as a white solid. Step 2: 24.8 g, 98 mmol of compound 2 was prepared in 50 mL of trifluoroacetic acid (TFA), and 12.5 g, 0.12 mol of KNO3 was added to the compound 2 solution at 0°C, and then stirred at room temperature for 0.5 hours. Then, the mixture was concentrated to dryness, and the crude product was dissolved in 500 mL of ethyl acetate and neutralized with a saturated aqueous solution of NaHCO3 to pH = 7. The organic layer was washed with water and brine in sequence, and dried over Na2SO4. Then, the mixture was filtered and concentrated to dryness to obtain 29 g, 99% of compound 3 as a yellow solid. Step 3: 29 g, 98 mmol of compound 3 was prepared in 500 mL of methanol / 125 mL of tetrahydrofuran (THF), and 5.54 g, 0.15 mol of NaBH4 was slowly added to the solution of compound 3 at 0°C. Then, the mixture was stirred at room temperature for 0.5 hours, and the mixture was concentrated to dryness. 200 mL of ether and 200 mL of water were added to the crude product, and it was filtered to obtain 29 g, 99% of compound 4 as a light yellow solid. Step 4: 29 g, 97 mmol of compound 4 was prepared in 250 mL of THF, and the solution of compound 4 was added to a LiOH solution formed by dissolving 7 g of LiOH in 125 mL of water, and stirred at room temperature for 2 hours. Then, the mixture was concentrated to remove THF. The solution was acidified to pH = 5 with 1N HCl. The residue was filtered to obtain 19.8 g (72%) of compound 5 in the form of a yellow solid. Step 5: 19.8 g, 70 mmol of compound 5 was prepared in 200 mL of THF, 17.2 g, 83 mmol of N, N'-dicyclohexylcarbodiimide (DCC) and 9.6 g, 83 mmol of N-hydroxysuccinimide (NHS) were added to the solution of compound 5, and stirred at room temperature for 6 hours. Then, the solid was filtered and the filtrate was concentrated to dryness, and the crude product was purified by column chromatography (EA / Hex=3 / 5) to obtain 9.4 g, 35% of a hard and yellow connector chemical formula α. FIG2 shows the nuclear magnetic resonance (NMR) analysis result of the connector chemical formula α, and the analysis data are as follows: 1H NMR (600 MHz, CDCl3) δ7.72 (s, 1H), 7.17 (s, 1H), 4.95 (d, J = 3.6 Hz, 2H), 4.19 (t, J = 5.9 Hz, 2H), 3.99 (s, 3H), 2.90 (t, J = 7.2 Hz, 2H), 2.85 (br s, 4H), 2.62 (br s, 1H), 2.30 (quin, J = 6.6 Hz, 2H)). FIG3 shows the liquid chromatography-tandem mass spectrometry (LC-MS / MS) analysis result of the connector chemical formula α. Example 2 [Preparation method of connector chemical formula β] FIG4 shows a preparation process of the connector chemical formula β shown below. The detailed synthesis steps of the connector chemical formula β will be described below with reference to FIG. 4 . Step 1: 2.5 g, 16.4 mmol of 4-hydroxy-3-methoxybenzaldehyde (Compound 1) was dissolved in 25 mL of DMF, and then 3.43 g, 24.8 mmol of K2CO3 and 4.58 g, 17.27 mmol of methyl 4-bromobutyrate were added, and stirred at 60° C. for 6 hours. Then, water was added to the resulting mixture at 0° C., and the resulting solid was filtered to obtain 5.3 g, 96% of Compound 2 as a white solid. Step 2: 3 g, 8.18 mmol of compound 2 was prepared in 70% 30 mL nitric acid / 8 mL acetic anhydride and reacted at 0°C for 6 hours. Then, the mixture was concentrated to dryness, and the crude product was dissolved in 50 mL ethyl acetate and neutralized with saturated aqueous NaHCO3 to pH = 7. The organic layer was washed with water, salt, and The mixture was then filtered and concentrated to dryness to obtain 3.2 g (94%) of compound 3 as a yellow solid. Step 3: 3.2 g, 8.39 mmol of compound 3 was prepared in 70 mL of CH3OH, and 0.64 g, 16.91 mmol of NaBH4 was slowly added to the solution of compound 3 at 0°C. Then, the mixture was reacted at 0°C for 6 hours, and the mixture was concentrated to dryness. 30 mL of ether and 30 mL of water were added to the crude product, and it was filtered to obtain 1.86 g, 58% of compound 4 as a light yellow solid. Step 4: 200 mg, 0.52 mmol of compound 4 was prepared in 10 mL methanol / 2 mL water, and the solution of compound 4 was added to 3.13 mmol of KOH solution and stirred at room temperature for 26 hours. Then, the mixture was filtered to obtain 190 mg, 98% of compound 5 as a yellow solid. Step 5: 190 mg, 0.51 mmol of compound 5 was prepared in 8 mL of dichloromethane (DCM) / 2 mL of methanol, 197 mg, 1.99 mmol of 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC) and 118 mg, 1.02 mmol of NHS were added to the solution of compound 5, and stirred at room temperature for 22 hours. Then, the solid was filtered and the filtrate was concentrated to dryness, and the crude product was purified by column chromatography (EA / Hex=3 / 5) to obtain 63 mg, 26% of a hard and yellow connector chemical formula β. Figure 5 shows the NMR analysis results of the connector chemical formula β, and the analysis data are as follows: 1H NMR (600 MHz, CDCl3) δ7.71 (s, 1H), 7.16 (s, 1H), 4.96 (d, J = 3.7 Hz, 2H), 4.09 (t, J = 6.8 Hz, 2H), 4.00 (s, 3H), 2.85 (d, J = 7.4 Hz, 4H), 2.61 (t, J = 7.5 Hz, 3H), 1.88 (h, J = 7.3 Hz, 2H), 1.76 (p, J = 7.6 Hz, 2H), 1.48 (h, J = 7.5 Hz, 2H), 1.45–1.35 (m, 6H), 1.35 (s, 3H), 1.30–1.25 (m, 2H), 0.92–0.84 (m, 1H). FIG6 shows the LC-MS / MS analysis results of connector formula β. Example 3 [Preparation method of connector chemical formula γ] FIG. 7 shows a preparation scheme of the connector formula γ as shown below. The detailed synthesis steps of the connector chemical formula γ will be described below with reference to FIG. 7 . Step 1: 500 mg, 2.51 mmol of 4-(hydroxymethyl)-2-methoxy-5-nitrophenol (Compound 1) was dissolved in 13 mL of CH3CN, and then 1.39 g, 10.04 mmol of K2CO3 and 1.12 g, 5.02 mmol of N-tert-butyloxycarbonyl-2-bromoethylamine (N-Boc-2-bromoethyl-amine) were added, and stirred at 90°C for 18 hours under Ar gas. Then, the obtained solid was filtered to obtain a concentrated liquid, which was then purified by column chromatography to obtain 234 mg, 27% of Compound 2 as a viscous liquid. Step 2: 210 mg, 0.61 mmol of compound 2 was prepared in 4 mL of CH2Cl2, and 0.4 mL of TFA was added and reacted at room temperature for 2 hours. Then, the mixture was concentrated to dryness by rotary evaporator, and the crude product was dissolved in 4 mL of dry CH2Cl2, and 314 mg, 0.85 mmol of disuccinimidyl suberate (DSS) and 0.25 mL, 1.83 mmol of triethylamine (Et3N) were added in sequence, and then reacted at room temperature for 2 hours. Then, the organic layer was removed by rotary evaporator, and purified by column chromatography to obtain 32 mg, 15% of the connector chemical formula γ as a viscous liquid. FIG8 shows the NMR analysis results of the connector chemical formula γ, and the analysis data are as follows: 1H NMR (600 MHz, CDCl3) δ7.73 (s, 1H), 7.23 (s, 1H), 6.17 (d, J = 6.1 Hz, 1H), 4.98 (s, 2H), 4.16 (t, J = 5.2 Hz, 2H), 4.01 (s, 3H), 3.73 (q, J = 5.4 Hz, 2H), 2.85 (s, 3H), 2.65-2.55 (m, 3H), 2.23 (t, J = 7.4 Hz, 2H), 1.81-1.63 (m, 9H), 1.49-1.30 (m, 6H). FIG9 shows the LC-MS / MS analysis results of the connector chemical formula γ. Example 4 [Preparation method of connector chemical formula δ] Figure 10 shows the preparation process of the connector chemical formula δ as shown below. As shown in Figure 10, compared with the connector chemical formulas α, β, and γ, the connector chemical formula δ has a polyethylene glycol (PEG) structure. The detailed synthesis steps of the connector chemical formula δ will be described below with reference to FIG. 10 . Step 1: 0.5 g, 2.5 mmol of 4-hydroxy-5-methoxy-2-nitrobenzaldehyde (Compound 1) was dissolved in 5 mL of DMF. Then, 0.53 g, 3.8 mmol, of K2CO3 and 1.09 g, 2.8 mmol, of ethyl 2-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)acetate were added at room temperature, and the mixture was stirred at 80°C for 6 hours. Then, 20 mL of water was added to the resulting mixture at 0°C, and the resulting solid was filtered to obtain 0.88 g, 84% of Compound 2 as a yellow solid. Step 2: 0.88 g, 2 mmol of compound 2 was prepared in 15 mL methanol / 5 mL THF and NaBH4 was slowly added, and the reaction was stirred at room temperature for 0.5 hours. The resulting mixture was diluted with 100 mL of ethyl acetate, and the organic layer was washed with 100 mL of water and 100 mL of brine in sequence, and then dried over Na2SO4. The resulting mixture was filtered and concentrated to dryness to obtain 0.87 g, 98% of compound 3 as a yellow solid. Step 3: 0.87 g, 2 mmol of compound 3 was prepared in 8 mL of THF, and 3 mL of an aqueous solution containing 0.64 g, 16.91 mmol of LiOH was slowly added at 0°C, and stirred at room temperature for 2 hours after the addition was complete. The mixture was concentrated to remove THF, and then acidified to pH = 5 with 1N HCl. The resulting solid was filtered to obtain 0.8 g, 99% of compound 4 as a light yellow solid. Step 4: 200 mg, 0.5 mmol of compound 4 was prepared in 3 mL of THF, and 120 mg, 0.6 mmol of EDC and 65 mg, 0.6 mmol of NHS were added to the solution of compound 4, and stirred at room temperature for 1 hour. The crude product was purified by column chromatography (Merck silica gel, 1.09385.9025) to obtain 78 mg, 31% of the connector chemical formula δ as a yellow oil. Figure 11 shows the NMR analysis results of the connector chemical formula δ, and the analysis data are as follows: 1H NMR (600 MHz, CDCl3) δ7.79 (s, 1H), 7.17 (s, 1H), 4.96 (s, 2H), 4.53 (s, 2H), 4.28 (dd, J = 5.5, 4.1 Hz, 2H), 4.00 (s, 3H), 3.96-3.91 (m, 2H), 3.79 (dd, J = 5.8, 3.2 Hz, 2H), 3.77-3.66 (m, 7H), 2.87 (s, 4H). Figure 12 shows the LC-MS / MS analysis results of the connector chemical formula δ. Example 5 [Analysis of Trastuzumab Conjugated with Different Hydrocarbon Chain Linkers by Sodium Dodecyl-Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE)] The following describes the SDS-PAGE analysis steps of trastuzumab bonded with hydrocarbon chain linkers: Step 1: 2.1 mg of the connector chemical formula α of Example 1 was mixed with 551 μL of dimethyl sulfoxide (DMSO) solvent to prepare a 10 mM connector chemical formula α solution; 2.7 mg of the connector chemical formula β of Example 2 was mixed with 579 μL of DMSO solvent to prepare a 10 mM connector chemical formula β solution; 1.1 mg of the connector chemical formula γ of Example 3 was mixed with 222 μL of DMSO solvent to prepare a 10 mM connector chemical formula γ solution; 2 mg of commercially available DSS (manufactured by Thermo Scientific) was mixed with 544 μL of DMSO solvent to prepare a 10 mM DSS solution. Step 2: Take four tubes of 5 mL (2 mg / mL) Herceptin antibody (Roche, trastuzumab), and add and mix 67.55 μL of 10 mM linker chemical formula α solution, 67.55 μL of 10 mM linker chemical formula β solution, 67.55 μL of 10 mM linker chemical formula γ solution, and 67.55 μL of 10 mM DSS solution in step 1, respectively, and then react at room temperature for 30 minutes to produce 1-T solution, 2-T solution, 3-T solution, and DSS-T solution. Step 3: The trastuzumab solutions with different linkers were placed in Ultracentrifugal filter ( Ultra filter device, add 11 mL of phosphate buffered saline (PBS), centrifuge at 2500 g for 30 minutes at 4-8°C, and remove The waste liquid below the Ultra filter device was removed, and 6 mL of PBS was added from the top. The mixture was centrifuged at 2500 g for 30 minutes at 4-8°C to remove The waste liquid below the Ultra filter device was then measured for its absorbance at 280 nm (OD280) to calculate the concentration. The antibody concentration was adjusted to 5 mg / mL with PBS, and 62.5% glycerol was mixed at a volume of 1 (antibody): 4 (glycerol) and stored at -20°C, so that the final antibody concentration of 1-T solution, 2-T solution, 3-T solution, and DSS-T solution was 1 mg / mL for subsequent use. Step 4: 5 μg of trastuzumab and trastuzumab with different hydrocarbon chain linkers were mixed with 10 μL of non-reducing sample buffer (3% SDS, 0.3% bromophenol blue, 15% glycerol and 188 mM Tris-HCl (pH 6.8)) and placed on a 10% SDS-polyacrylamide gel and analyzed by electrophoresis in 1× Tris-glycine SDS-electrophoresis buffer (1 L, 3.03 g Tris, 14.4 g glycine, 2% SDS). Tetra Vertical Electrophoresis Cell (1658004 / BIO-RAD). The electrophoresis conditions are: 100V constant voltage for about 20 minutes, then change to 160V constant voltage when the indicator enters the concentrated gel. When the gel plate reaches the bottom, the electrophoresis is stopped. The whole process takes about 80 minutes. Step 5: Take out the SDS-polyacrylamide gel and stain it in staining solution (0.08% (w / v) Coomassie Brilliant Blue R-250, 50% (v / v) methanol, 10% (v / v) acetic acid) for about 30 minutes. Pour out the staining solution and add destaining solution (50% (v / v) methanol, 10% (v / v) acetic acid). Shake slowly and pay attention to changing the destaining solution until the gel is clean and the background is clear. Experimental results: FIG13 shows the SDS-PAGE analysis results of trastuzumab bonded with different hydrocarbon chain linkers. As shown in FIG13 , compared with the trastuzumab (T) in the control group, the molecular weight of the commercial control group DSS-T increases due to antibody cross-linking, so the non-reducing SDS-PAGE electrophoresis analysis shows that DSS-T also exists at a higher molecular weight position (>245kDa). Such antibody cross-linking reaction will affect the subsequent bonding with cells. However, the experimental groups: 1-T, 2-T and 3-T have no antibody cross-linking reaction, so the molecular weight of the experimental group antibody on SDS-PAGE is consistent with that of the control group trastuzumab (T). Example 6 [Cellular Stability Test of Linker-bound Trastuzumab] The following describes the steps for comparing the degree of binding of trastuzumab bound to adipose-derived mesenchymal stem cells (ADMSC) with different hydrocarbon linkers. Step 1: 1 mL of frozen human adipose-derived mesenchymal stem cells (ADMSC) (TCI GENE; Lot. no. 20210816) and 10 mL of PBS were transferred to a 15 mL centrifuge tube, centrifuged at 400 g for 5 minutes, and replaced with 10 mL of mesenchymal stem cell (MSC) culture medium (Minimum Essential Medium α (αMEM) / 5% EliteGro (human platelet lysate; EG) / 1 ng / ml fibroblast growth factor β (FGF-β) / 20 ng / ml platelet-derived growth factor BB (PDGF-BB)), and then transferred to a 10 cm cell culture dish and cultured at 37°C, 5% CO2 for three days. CTS TM TrypLE TM Select enzyme (Gibco TM , A1285901) treated ADMSC cells and transferred to a 15 mL centrifuge tube. Centrifuge at 400 g for 5 minutes at 4-8 °C, remove the supernatant, wash with PBS and centrifuge twice. Finally, dissolve the ADMSC cells with PBS and adjust the concentration of ADMSC cells to 2x10 6 Finally, the solution was divided into 6 tubes with 1 mL per tube and labeled as control group, control group and experimental group (1), (2), (3) and (4). Step 2: [Preparation of control group, control group and experimental group] The control group was a mixture formed by adding 1 mL of PBS and 1 mL of ADMSC cell solution; the control group was 940 μL of PBS and added with 60 μL of 1 mg / mL trastuzumab solution and DSS-T solution; the experimental group was 940 μL of PBS and added with 60 μL of 1 mg / mL 1-T, 2-T and 3-T solutions. Then, the solution was uniformly irradiated with UV at a wavelength of 365 nm for 10 seconds and paused for 10 seconds each time, for a total of two times, and then 1 mL of MSC cell solution in step 1 was added to form a final concentration of 30 μg / mL of trastuzumab antibody and a final concentration of 30 μg / mL of trastuzumab bonded with different connectors. Then, the mixture of the control group, the control group and the experimental group was allowed to stand at 4°C for 10 minutes. Step 3: Centrifuge the mixture from step 2 at 400g for 5 minutes at 4-8°C, remove the supernatant, wash twice with 10 mL PBS, and finally dissolve the cells with PBS to adjust the cell concentration to 1x10 6 cells / mL for subsequent experiments. Step 4: Take out 200 μL of each solution in step 3 into a 1.5 mL test tube (Eppendorf), dilute goat F(ab')2 Anti-Human IgG-(Fab')2(PE) (abcam, cat. no. ab98606) with PBS at a volume ratio of 1:100, take 200 μL and add it to the solution of each group in step 3, and react on ice for 15 minutes. Then, add 800 μL PBS, centrifuge at 400g for 5 minutes at 4-8°C, remove the supernatant, wash with 1 mL PBS, centrifuge twice, remove the supernatant, and add 200 μL PBS to each group to dissolve the cells, and finally analyze by flow cytometry (fluorescence activated cell sorting, FACS). Experimental results: The antibody staining on the ADMSC cell membrane was performed with goat F(ab')2 anti-human IgG-(Fab')2 (PE), and the PE signal was analyzed by flow cytometry to obtain the strength of antibody binding to ADMSC. Figure 14 shows the results of the comparative test of the binding degree of trastuzumab to ADMSC bound by different hydrocarbon chain linkers. As shown in Figure 14, the experimental groups: 1-T MSC, 2-T MSC, and 3-T MSC successfully bound to the NK cell surface compared with the control group trastuzumab MSC and the control group DSS-T MSC, among which 1-T had the strongest binding ability with ADMSC cells. Example 7 [Analysis of the degree of binding of trastuzumab with different hydrocarbon chain linkers to natural killer NK cells] The following describes the steps for comparing the degree of binding of trastuzumab bound to NK cells with different hydrocarbon chain linkers. Step 1: 1 mL of frozen human NK cells (TCI GENE; Lot. no. 20210816) and 10 mL of PBS were transferred to a 15 mL centrifuge tube and washed by centrifugation at 400 g for 5 minutes. The NK cell concentration was adjusted to 5 × 10 cells / mL with NK cell culture medium (Gibco Roswell Park Memorial Institute Medium (RPMI), 5% EliteGro, 500 IU / mL rhIL-2). 5 Cells / mL and transferred to T75 flask for culture. After one day of culture at 37°C and 5% CO2, the washing and replacement buffer was removed by the following method (A) or (B): (A) NK cells were transferred to a 15 mL centrifuge tube and centrifuged at 400 g at 4-8°C for 5 minutes. The supernatant was removed and the tube was washed with 10 mL PBS and centrifuged twice. Finally, the NK cells were re-lysed with PBS and the concentration of NK cells was adjusted to 2x10 6 cells / mL. (B) NK cells were transferred to a 50 mL centrifuge tube and centrifuged at 400 g at 4-8°C for 5 minutes. The supernatant was removed and the tube was washed with 50 mL PBS and centrifuged once. Finally, the NK cells were re-lysed with PBS and the concentration of NK cells was adjusted to 2 x 10 6 cells / mL. Next, 6 tubes were prepared with 1 mL of the solution in each tube and labeled as the control group, comparison group, and experimental group (1), (2), (3), and (4). Step 2: [Preparation of control group, control group and experimental group] The control group was a mixture of 1 mL of PBS and 1 mL of NK cell solution; the control group was 940 μL of PBS and 60 μL of 1 mg / mL trastuzumab solution and DSS-T solution were added; the experimental group was 940 μL of PBS and 60 μL of 1 mg / mL 1-T, 2-T and 3-T solutions were added. Then, the mixture was mixed with 1 mL of NK cell solution in step 1 at a volume ratio of 1:1 to make the final concentration of trastuzumab 30 μg / mL and the final concentration of NK cells 1x10 6 Finally, the UV wavelength was set at 365 nm to 400 mJ / cm 2The solution was irradiated uniformly, and the mixture of the control group, the control group, and the experimental group was allowed to stand at 2-8°C for 10 minutes. Step 3: Divide the mixture from step 2 into the following two groups for subsequent experiments: (A) For small-scale cell experiments: Transfer the mixture from step 2 to a 15 mL centrifuge tube and add an equal volume of PBS / 1% HSA solution. Centrifuge at 400 g for 5 minutes at 4-8°C, remove the supernatant, and then add 10 mL Wash and centrifuge twice with PBS / 1% HSA, dissolve NK cells according to the solution required for the experiment, and adjust the NK cell concentration to 2x10 6 cells / mL. (B) For large-scale animal testing: Transfer the mixture from step 2 to a 50 mL centrifuge tube and add an equal volume of PBS / 1% HSA solution. Centrifuge at 400 g at 4-8°C for 5 minutes. Remove the supernatant and wash with 50 mL PBS / 1% HSA and centrifuge once. Add NK cells according to the experimental solution and adjust the NK cell concentration to 2 x 10 6 cells / mL. Step 4: Take out 200 μL of the solution of each group in step 3 into a 1.5 mL test tube (Eppendorf), dilute goat F(ab')2 anti-human IgG-(Fab')2(PE) (abcam, cat. no. ab98606) with PBS at a volume ratio of 1:100, take 200 μL and add it to the solution of each group in step 3. At the same time, add 5 μL of CD16 monoclonal antibody (eBioscience TM .17-0168-42) and reacted at 4°C for 30 minutes. 800 μL PBS was added and centrifuged at 400g for 5 minutes at 4-8°C, and the supernatant was removed. The cells were washed and centrifuged twice with 1 mL PBS, and the supernatant was removed. 200 μL PBS was added to each group to dissolve the cells, and finally analyzed by flow cytometry (FACS). Experimental results: NK cell membrane antibody staining was performed with goat F(ab')2 anti-human IgG-(Fab')2 (PE), and CD16 was analyzed by flow cytometry (FACS). +NK cell PE signal, thereby obtaining the strength of trastuzumab binding to NK cells. Figure 15 shows the results of the comparative test of trastuzumab binding to NK cells with different hydrocarbon chain connectors. As shown in Figure 15, compared with the trastuzumab NK in the control group and the DSS-T NK in the commercial control group, the experimental groups 1-T NK, 2-T NK and 3-T NK successfully bound to the surface of NK cells, among which 1-T had the strongest ability to bind to NK cells. As shown in Examples 6 and 7, among the four hydrocarbon chain connectors, the antibody prepared by the connector chemical formula α has the best ability to bind to cells. Example 8 [Analysis of the Cytotoxicity of Trastuzumab-NK Cells with Different Hydrocarbon Chain Linkers to BT474 Breast Cancer Cells] The following describes the steps for comparing the cytotoxicity of trastuzumab-NK cells bound with different hydrocarbon chain linkers against BT474 breast cancer cells. Step 1: At 37°C and 5% CO2, the cells were cultured in a 10 cm cell culture dish with 10 mL of cell culture medium (Iscove's Modified Dulbecco's Medium (IMDM) / 10% fetal bovine serum (FBS) / 30 ng / mL epidermal growth factor ( BT474 breast cancer cells were cultured with EGF for three days. The cell suspension was removed and washed with 10 mL PBS, followed by the addition of 1 mL CTS TM TrypLE TM Select enzyme and react at 37°C, 5% CO2 for 5 minutes. Then, add 10mL cell culture medium to harvest the cells, transfer them to a 15mL centrifuge tube, and centrifuge at 400g for 5 minutes at 4-8°C. After removing the supernatant, wash with PBS and centrifuge twice. Finally, dissolve the BT474 cells with PBS and adjust the cell concentration to 5x10 6 -1x10 7 cells / mL. Step 2: Add 20 μL DMSO solvent to the Deep Red reagent tube, take out 5 μL Deep Red solution and add it to 1 μM CellTracker prepared in 5 mL PBS. TM Deep Red stain (Invitrogen TM , C34565) solution and store in the dark. 2 mL of breast cancer cell BT474 and 2 mL of 1 μM Deep Red solution were mixed in a 1:1 volume ratio to a total of 4 mL, and then reacted in the dark at room temperature for 10 minutes. Step 3: Take 10mL of cell culture medium (IMDM / 10% FBS / 30ng / mL EGF) and centrifuge twice to wash BT474 cells with Deep Red dye, 400g 4-8℃, 5 minutes. Adjust the concentration of Deep Red stained breast cancer cell BT474 cells to 1x10 5 cells / mL. Step 4: The NK cells of the experimental group, control group and control group of Example 6 were compared with CellTracker TM BT474 cells were stained with Deep Red dye and mixed at a ratio of 1:1, 5:1 and 10:1 to a final volume of 200 μL, placed in a 96-well plate flat bottom, and reacted at 37°C for 4 hours. Step 5: Prepare 100 μL of Annexin V / PI solution (98.5 μL 1X binding buffer plus 1 μL Annexin V and 0.5 μL PI). Take out 200 μL of the cytotoxic cells that have been reacting for 4 hours and mix them with 100 μL of Annexin V / PI solution. After reacting for 5 minutes at room temperature in the dark, analyze Deep Red by flow cytometry (FACS). + / Annexin V + / PI + Cell populations. Experimental results: Select Deep Red first + BT474 cell population, and then analyzed its Annexin V + / PI + The cell ratio of BT474 cells was calculated by subtracting the spontaneous death of BT-474 cells (Annexin V + / PI + ) values ​​as a comparison of NK cell cytotoxicity (specific lysis) effects. Figure 16 shows the effects of trastuzumab-NK cells with different hydrocarbon chain linkers on the cytotoxicity of solid tumor breast cancer cells. As shown in Figure 16, compared with the NK in the control group and the trastuzumab NK and DSS-T NK in the control group, the NK cells with linkers-antibodies in the experimental group have better cytotoxicity, among which the 1-T NK cells in the experimental group have The best cytotoxicity is 46.5%, 82.9% and 78.9% at E / T ratios (effector to target cell ratio) of 1:1, 5:1 and 10:1, respectively. The cytotoxicity increases with the increase in the proportion of NK cells. The experimental results show that 1-T NK cells are the cells with the strongest cytotoxicity among the four types of connector-antibody-bound NK cells. It can be seen from Examples 6, 7 and 8 that the antibody prepared by the connector chemical formula α has the best cell binding ability among the four types of connectors, and has better cell efficacy after binding to cells. Example 9 [Analysis of apoptosis caused by trastuzumab-NK cells with different linkers on three solid tumor cancer cells] The following describes the steps for comparing the apoptosis induced by trastuzumab-NK cells conjugated with different linkers on three solid tumor cancer cells. Step 1: 1 mL of frozen human NK cells (TCI GENE; Lot. no. 20220627) and 10 mL of PBS were transferred to a 15 mL centrifuge tube and washed by centrifugation at 400 g for 5 minutes. The NK cell concentration was adjusted to 5 × 10 cells / mL with NK culture medium (RPMI, 5% EliteGro, 500 IU / mL rhIL-2). 5 Cells / mL were transferred to T75 culture flasks for culture. After one day of culture at 37°C and 5% CO2, the washing and replacement buffers were removed by the following method (A) or (B): (A) NK cells were transferred to a 15 mL centrifuge tube and centrifuged at 400 g at 4-8°C for 5 minutes. The supernatant was removed and the tube was washed with 10 mL PBS and centrifuged twice. Finally, the NK cells were re-lysed with PBS and the concentration of NK cells was adjusted to 2x10 6 cells / mL. (B) NK cells were transferred to a 50 mL centrifuge tube and centrifuged at 400 g at 4-8°C for 5 minutes. The supernatant was removed and the tube was washed with 50 mL PBS and centrifuged once. Finally, the NK cells were re-lysed with PBS and the concentration of NK cells was adjusted to 2 x 10 6 cells / mL. Finally, the solution was divided into 6 tubes with 1 mL in each tube and labeled as control group, comparison group, and experimental group (1), (2), (3), and (4), respectively. Step 2: [Preparation of control group, control group and experimental group] The control group was a mixture of 1 mL of PBS and 1 mL of NK cell solution; the control group was 940 μL of PBS and 60 μL of 1 mg / mL trastuzumab solution; the experimental group was 940 μL of PBS and 60 μL of 1 mg / mL 1-T, 2-T, 3-T and 4-T solutions (1-T, 2-T, 3-T are trastuzumab with hydrocarbon chain connectors; 4-T is trastuzumab with δ-bond in chemical formula) were added. Then, it was mixed with 1 mL of NK cell solution in step 1 at a volume ratio of 1:1. The final concentration of trastuzumab was 30 μg / mL, and the final concentration of NK cells was 1x10 6 Finally, the UV wavelength was set at 365 nm to 400 mJ / cm 2 The solution was irradiated uniformly, and the mixture of the control group, the control group, and the experimental group was allowed to stand at 2-8°C for 10 minutes. Step 3: Divide the mixture from step 2 into the following two groups for subsequent experiments: (A) For small-scale cell experiments: Transfer the mixture from step 2 to a 15 mL centrifuge tube and add an equal volume of PBS / 1% HSA solution. Centrifuge at 400 g for 5 minutes at 4-8°C, remove the supernatant, wash and centrifuge twice with 10 mL PBS / 1% HSA, and dissolve the NK cells according to the solution required for the experiment, and adjust the NK cell concentration to 2 x 10 6 cells / mL. (B) For large-scale animal testing: Transfer the mixture from step 2 to a 50 mL centrifuge tube and add an equal volume of PBS / 1% HSA solution. Centrifuge at 400 g at 4-8°C for 5 minutes. Remove the supernatant and wash once with 50 mL PBS / 1% HSA. Centrifuge once to obtain NK cells according to the experimental requirements and adjust the NK cell concentration to 2 x 10 6 cells / mL. Step 4: [Bond Analysis] Take out 200 μL of each solution in step 2 into a 1.5 mL test tube (Eppendorf), dilute goat F(ab')2 anti-human IgG-(Fab')2(PE) (abcam, cat. no. ab98606) with PBS at a volume ratio of 1:100, take 200 μL and add it to the solution of each group in step 3, and react at 4°C for 15 minutes. Add 800 μL PBS and centrifuge at 400g for 5 minutes at 4-8°C, remove the supernatant, wash and centrifuge twice with 1 mL PBS, remove the supernatant, add 200 μL PBS to each group to dissolve the cells, and analyze them by flow cytometry (FACS). Step 5: [Cancer cell fluorescence calibration] Breast cancer cells BT474, human colon cancer cells Colo205, and human pancreatic cancer cells BxPC-3 were cultured in 10 cm cell culture dishes at 37°C and 5% CO2 for three days with 10 mL of cell culture medium (IMDM / 10% FBS / 30 ng / mL EGF) and (RPMI / 10% FBS). The cell culture medium was removed and washed with 10 mL of PBS, and 1 mL of CTS was added. TM TrypLE TM Select enzyme and react at 37°C, 5% CO2 for 5 minutes. Then, add 10mL cell culture medium to harvest the cells and transfer to a 15mL centrifuge tube. Centrifuge at 400g for 5 minutes at 4-8°C, remove the supernatant, wash with PBS and centrifuge twice. Finally, lyse the cancer cells with PBS and adjust the cell concentration to 5x10 6 -1x10 7 cells / mL. Add 20 μL DMSO solvent to Deep Red Reagent tube, take out 5μL Deep Red solution and add it to 5mL PBS to prepare 1μM CellTracker TM Deep Red stain (Invitrogen TM ,C34565) solution and store it in the dark. Mix 2mL cancer cell fluid and 2mL 1μM Deep Red solution in a 1:1 volume ratio to make a total of 4mL, and then react in the dark at room temperature for 10 minutes. Take 10mL cancer cell culture medium and centrifuge and wash Deep Red stained cancer cells twice. The conditions are: 400g, 4-8℃, 5 minutes. Adjust the cell concentration of Deep Red stained cancer cells to 1x10 with cell culture medium. 5 cells / mL. Step 6: [Apoptosis analysis] Take the NK cells and CellTracker of the experimental group, control group and control group of the embodiment TM Cancer cells stained with Deep Red dye were mixed in a 96-well plate at a ratio of 5:1 to a final volume of 200 μL and reacted at 37°C for 4 hours. 100 μL Annexin V / PI solution was prepared (98.5 μL 1X binding buffer plus 1 μL Annexin V and 0.5 μL PI). 200 μL of the cytotoxic cells that reacted for 4 hours were taken out and mixed with 100 μL Annexin V / PI solution. After reacting at room temperature in the dark for 5 minutes, Deep Red was analyzed by flow cytometry (FACS). + / Annexin V- / PI- cell population. Experimental results: The antibody on the NK cell membrane was stained with goat F(ab')2 anti-human IgG-(Fab')2 (PE), and the PE signal of NK cells was analyzed by flow cytometry (FACS) to obtain the strength of trastuzumab binding to NK cells. Figure 17 shows the results of the degree of binding between trastuzumab and NK with different linkers. As shown in Figure 17, compared with the control group trastuzumab NK, the experimental groups 1-T NK, 2-T NK, 3-T NK and 4-T NK can all successfully bind to the surface of NK cells. Next, select Deep Red + The cancer cell populations were analyzed, and the proportion of NK-induced cancer cell apoptosis ((100% - cancer cell viability % (Annexin V- / PI-)) was analyzed. After deducting the spontaneous apoptotic cells of cancer cells, the apoptosis results of cancer cells caused by trastuzumab-NK cells with different linkers on three solid tumors (breast cancer / colon cancer / pancreatic cancer cells) were compared. Figures 18A-18C show the results of cancer cell apoptosis caused by trastuzumab NK cells with different linkers toxic to three solid tumor cancer cells. As shown in Figures 18A-18C, compared with the control group NK and the control group Hecanping+NK, the four different linker-antibody-bound NK cells in the experimental group all have better cell apoptosis effects on three solid tumors (including: breast cancer (BT474), colon cancer (Colo205), pancreatic cancer cells (BxPC3)), among which the experimental group 1-T NK and 4-T NK cells have better cell The apoptosis ability in three solid tumors (breast cancer, colon cancer, pancreatic cancer cells) was 72.2% / 66.2%, 57.7% / 58.9% and 61.4% / 57.1%, respectively, indicating that the trastuzumab-NK with a 4-T linker bonded with a PEG structure has a similar ability to induce apoptosis of solid tumor cells compared to the trastuzumab-NK with a hydrocarbon chain linker bonded. In addition, the experiment proved that the strategy of trastuzumab-NK cells killing solid tumor cells with different linkers can be extended to other solid tumor cancers besides breast cancer. Example 10 [Comparative analysis of the reaction time required for linker-bound trastuzumab to bind to NK cells] The following describes the steps for comparing the reaction time required for linker-bound trastuzumab to bind to NK cells. Step 1: Transfer 1 mL of frozen human NK cells (TCI GENE; Lot. no. 20210806) and 10 mL of PBS to a 15 mL centrifuge tube, centrifuge at 400 g for 5 minutes, wash, and replace with 10 mL of NK culture medium (RPMI, 5% EG, 500 IU / mL rhIL-2), and transfer to a 10 cm cell culture dish for culture. After one day of culture at 37°C and 5% CO2, remove the washing and replacement buffer using the following method (A) or (B): (A) NK cells were transferred to a 15 mL centrifuge tube and centrifuged at 400 g at 4-8°C for 5 minutes. The supernatant was removed and the tube was washed with 10 mL PBS and centrifuged twice. Finally, NK cells were re-lysed with PBS and the concentration of NK cells was adjusted to 2 x 10 6 cells / mL. (B) NK cells were transferred to a 50 mL centrifuge tube and centrifuged at 400 g at 4-8°C for 5 minutes. The supernatant was removed and the tube was washed with 50 mL PBS and centrifuged once. Finally, NK cells were re-lysed with PBS and the concentration of NK cells was adjusted to 2 x 10 6 cells / mL. Finally, the solution was divided into 5 tubes with 1 mL in each tube and labeled as control group, comparison group, and experimental group (1), (2), and (3), respectively. Step 2: [Preparation of control group, control group and experimental group] The control group was a mixture of 1 mL of PBS and 1 mL of NK cell solution; the control group was 900 μL of PBS and 100 μL of 1 mg / mL trastuzumab solution; the experimental group was 900 μL of PBS and 100 μL of 1 mg / mL linker-bound trastuzumab solution. Then, it was mixed with 1 mL of NK cell solution in step 1 at a volume ratio of 1:1 to make the final concentration of trastuzumab 50 μg / mL and the final concentration of NK cells 1x10 6 Then, UV with a wavelength of 365 nm was set to 400 mJ / cm 2 Irradiate the solution evenly and place the control group and control The mixture of the control group and the experimental group was allowed to stand at 2-8°C for 10 minutes. Finally, the mixture of the control group, the control group and the experimental group was allowed to stand at 4°C for 1, 5 and 10 minutes, and then the reaction stop solution (RPMI / 10% FBS) was added to stop the reaction of the linker-bound trastuzumab binding to the cells. Step 3: Divide the mixture from step 2 into the following two groups for subsequent experiments: (A) For small-scale cell experiments: Transfer the mixture from step 2 to a 15 mL centrifuge tube and add an equal volume of PBS / 1% HSA solution. Centrifuge at 400 g for 5 minutes at 4-8°C, remove the supernatant, wash and centrifuge twice with 10 mL PBS / 1% HSA, and dissolve the NK cells according to the solution required for the experiment, and adjust the NK cell concentration to 2 x 10 6 cells / mL. (B) For large-scale animal testing: Transfer the mixture from step 2 to a 50 mL centrifuge tube and add an equal volume of PBS / 1% HSA solution. Centrifuge at 400 g at 4-8°C for 5 minutes. Remove the supernatant and wash once with 50 mL PBS / 1% HSA. Centrifuge once to obtain NK cells according to the experimental requirements and adjust the NK cell concentration to 2 x 10 6 cells / mL. Step 4: Take out 200 μL of the solution from each group in step 3 into a 1.5 mL test tube (Eppendorf), and dilute goat F(ab')2 anti-human IgG-(Fab')2(PE) (abcam, cat. no. ab98606) with PBS at a volume ratio of 1:100, and react at 4°C for 30 minutes. Add 800 μL PBS and centrifuge at 400g for 5 minutes at 4-8°C, remove the supernatant, wash with 1 mL PBS, centrifuge twice, remove the supernatant, add 200 μL PBS to each group to dissolve the cells, and analyze them by flow cytometry (FACS). Experimental results: The antibody on the NK cell membrane was stained with goat F(ab')2 anti-human IgG-(Fab')2 (PE), and the PE signal intensity was analyzed by flow cytometry (FACS) to obtain the degree of trastuzumab binding to NK cells. Figure 19 shows the results of different binding reaction times of linker-bound trastuzumab to NK cells. As shown in Figure 19, compared with the trastuzumab in the control group, the linker-bound trastuzumab in the 1-point, 5-point and 10-point experimental groups all successfully bound to the surface of NK cells. Figure 20 shows the extent to which the linker-bound trastuzumab binds to the NK cell surface at different times. As shown in Figure 20, the geometric means (Geo Mean) of the 1-point, 5-point, and 10-point experimental groups are 194, 228, and 222, respectively, so the difference is not large, indicating that the linker-bound trastuzumab can effectively bind to the NK cell surface in just 1 minute. Example 11 [Analysis of the binding ability of linker-bound trastuzumab to different cells: platelets] The following describes the steps for analyzing the binding ability of linker-conjugated trastuzumab to different cells: platelets. Step 1: After mixing 15 mL of fresh blood with PBS at a ratio of 1:1, add 15 mL of Ficoll-Paque Plus / Premium to a 50 c.c. centrifuge tube, then slowly add the blood and PBS mixture and centrifuge at 600g for 20 minutes, and turn the speed down to 0. After centrifugation, remove the upper plasma, take the peripheral blood mononuclear cell (PBMC) layer to a new 50 c.c. centrifuge tube, add PBS to 40 mL, and centrifuge at 400g for 5 minutes. Take the supernatant (containing platelets) to a new 50 c.c. centrifuge tube, add PBS to 40 mL, and centrifuge at 800g for 10 minutes. Remove the supernatant and add PBS to 40 mL, and centrifuge at 800g for 10 minutes. Finally, remove the supernatant, use PBS to dissolve the cells, and adjust the cell concentration to 1x10 7 cells / mL for subsequent experiments. Step 2: [Preparation of control group, control group and experimental group] The control group was a mixture formed by adding 1mL of PBS and 1mL of platelet cell solution; the control group was 900μL of PBS and added with 100μL of 1mg / mL trastuzumab solution; the experimental group was 900μL of PBS and added with 100μL of 1mg / mL trastuzumab solution with a linker chemical formula α. The solution was uniformly irradiated with UV at a wavelength of 365nm for 10 seconds each time, and paused for 10 seconds, for a total of two times, and then 1mL of platelet cell solution in step 1 was added to make a mixture with a final concentration of 50μg / mL of trastuzumab antibody and a final concentration of 50μg / mL of trastuzumab with a linker chemical formula α. Then, the mixture of the control group, the control group and the experimental group was placed at 4°C for 10 minutes. Step 3: The mixture in step 2 was centrifuged at 800 g for 5 minutes at 4-8°C, and the supernatant was removed. The cells were then washed and centrifuged twice with 10 mL PBS. Finally, the cells were lysed with cell culture medium (RPMI / 10% FBS) and the cell concentration was adjusted to 1x10 6 cells / mL for subsequent experiments. Step 4: Take out 200 μL of each solution from step 3 and put it into a 1.5 mL test tube (Eppendorf). Dilute goat F(ab')2 anti-human IgG-(Fab')2(PE) (abcam, cat. no. ab98606) with PBS at a volume ratio of 1:100, take 200 μL and add it to the solution of each group. At the same time, add 5 μL of FITC anti-human CD41 antibody to each group. 303704) and reacted at 4°C for 30 minutes. 800 μL PBS was added and centrifuged at 800 g for 5 minutes at 4-8°C, the supernatant was removed, and the cells were washed and centrifuged twice with 1 mL PBS. Then, the supernatant of each group was removed, 200 μL PBS was added to dissolve the cells, and finally analyzed by flow cytometry (FACS). Experimental results: CD41 was detected by goat F(ab')2 anti-human IgG-(Fab')2 (PE) + The platelet cell membrane was stained with antibodies, and the PE signal intensity was analyzed by flow cytometry (FACS) to obtain the degree of antibody binding to platelet cells. Figure 21 shows the results of the binding reaction of trastuzumab bound by the linker (chemical formula α) to platelets. As shown in Figure 21, the trastuzumab bound by the linker (chemical formula α) in the experimental group successfully bound to CD41 + Platelet cell surface. FIG. 22 shows the effect of trastuzumab bound by the linker (chemical formula α) on CD41 + As shown in Figure 22, compared with the trastuzumab in the control group, the trastuzumab bound by the linker (chemical formula α) in the experimental group has a stronger affinity for CD41 + Platelets have better bonding ability. Example 12 [Analysis of the binding ability of linker-bound trastuzumab to different cells: CD3 + / CD8 + T cells] The following is an analysis of the binding ability of linker-bound trastuzumab to different cells: CD3 + / CD8 + T cell steps. Step 1: After mixing 15 mL of fresh blood with PBS at a ratio of 1:1, add 15 mL of Ficoll-Paque Plus / Premium to a 50 c.c. centrifuge tube, then slowly add the blood and PBS mixture, centrifuge at 600 g for 20 minutes and turn the speed down to 0. After centrifugation, remove the upper plasma layer, take the PBMC layer to a new 50 c.c. centrifuge tube, add PBS to 40 mL, centrifuge at 400 g for 5 minutes, and remove the supernatant. Add PBS to 40 mL, centrifuge at 400 g for 5 minutes, remove the supernatant, and finally add PBS to adjust the cell concentration to 2x10 6 cells / mL for subsequent experiments. Step 2: [Preparation of control group, control group and experimental group] The control group was a mixture of 1 mL of PBS and 1 mL of PBMC cell solution; the control group took 900 μL of PBS and added 100 μL of 1 mg / mL Heaiping solution; the experimental group took 900 μL of PBS and added 100 μL of 1 mg / mL linker-bound trastuzumab solution. The solution was uniformly irradiated with UV at a wavelength of 365 nm for 10 seconds each time, and then paused for 10 seconds, for a total of two times. Step 1 was added. 1 mL of PBMC cell solution was added to make a mixture with a final concentration of 50 μg / mL of trastuzumab antibody and a mixture with a final concentration of 50 μg / mL of trastuzumab linked to the linker. Then, the mixture of the control group, the control group and the experimental group was allowed to stand at 4°C for 10 minutes. Step 3: The mixture in step 2 was centrifuged at 400 g for 5 minutes at 4-8°C, and the supernatant was removed. The cells were washed and centrifuged twice with 10 mL PBS, and finally the cells were lysed with cell culture medium (RPMI / 10% FBS) to adjust the cell concentration to 1x10 6 cells / mL for subsequent experiments. Step 4: Take out 200 μL of the solution of each group in step 3 into a 1.5 mL test tube (Eppendorf), and dilute goat F(ab')2 anti-human IgG-(Fab')2(PE) (abcam, cat. no. ab98606) with PBS at a volume ratio of 1:100, and then take 200 μL and add it to the solution of each group. Add 5 μL FITC anti-human CD3 antibody (BioLegend.317306) and 5 μL PerCP / Cyanine5.5 anti-human CD8 antibody (BioLegend.344710) to each group at the same time, and then place it at 4°C for 30 minutes. Then, add 800 μL PBS and centrifuge at 400g for 5 minutes at 4-8°C, remove the supernatant, wash and centrifuge twice with 1 mL PBS, remove the supernatant of each group, add 200 μL PBS to dissolve the cells, and finally analyze by flow cytometry (FACS). Experimental results: CD3 was detected with goat F(ab')2 anti-human IgG-(Fab')2 (PE) + / CD8 + The antibody staining on the T cell membrane was performed, and the PE signal was analyzed by flow cytometry (FACS) to obtain the degree of antibody binding to PBMC cells. FIG. 23 shows the effect of trastuzumab bound by a linker (chemical formula α) on CD3 + / CD8 + As shown in Figure 23, the trastuzumab bound by the linker (chemical formula α) in the experimental group successfully bound to CD3 + / CD8 + T cell surface. FIG. 24 shows the effect of trastuzumab bound by the linker (chemical formula α) on CD3 + / CD8 + As shown in Figure 24, compared with the trastuzumab in the control group, the trastuzumab bound by the linker (chemical formula α) in the experimental group had a stronger binding capacity to CD3 + / CD8 + T cells have better bonding ability. Example 13 [Cellular Stability Test of Linker-bound Trastuzumab] The following describes the steps for the cell-based stability test of linker-bound trastuzumab. Step 1: After 15 mL of fresh blood was mixed with PBS at a ratio of 1:1, 15 mL of blood was added to a 50 c.c. centrifuge tube. Ficoll-Paque Plus / Premium, then slowly add blood and PBS mixture, centrifuge at 600g for 20 minutes and turn the speed down to 0. After centrifugation, remove the upper plasma, take the PBMC layer into a new 50cc centrifuge tube, add PBS to 40mL and centrifuge at 400g for 5 minutes. Remove the supernatant, add PBS to 40mL, centrifuge at 400g for 5 minutes and remove the supernatant. Finally, add PBS and adjust the cell concentration to 2x10 6 cells / mL for subsequent experiments. Step 2: [Preparation of control group, control group and experimental group] The control group was a mixture formed by adding 1mL of PBS and 1mL of PBMC cell solution; the control group was 900μL of PBS and 100μL of 1mg / mL of Hecanping solution was added; the experimental group was 900μL of PBS and 100μL of 1mg / mL of trastuzumab solution was added. The solution was irradiated with UV at a wavelength of 365nm for 10 seconds and paused for 10 seconds, for a total of two times. Then, 1mL of PBMC cell solution in step 1 was added to make a mixture with a final concentration of 50μg / mL of trastuzumab antibody and a final concentration of 50μg / mL of trastuzumab linked to the linker. Then, the mixture of the control group, the control group and the experimental group was allowed to stand at 4°C for 10 minutes. Step 3: The mixture in step 2 was centrifuged at 400g for 5 minutes at 4-8°C, and the supernatant was removed. The cells were then washed and centrifuged twice with 5 mL PBS. Finally, the cells were lysed with cell culture medium (RPMI / 10% FBS) to adjust the cell concentration to 1x10 6 cells / mL for subsequent experiments. Step 4: The linker-bound trastuzumab-PBMC cells, trastuzumab-PBMC cells and PBMC cells were seeded into a 96-well flat-bottom plate with a final volume of 200 μL / well. Each group of 6 wells was placed in a 37°C cell culture incubator and supplemented with 50 μL of cell culture medium every 24 hours. Step 5: Every 24 hours, 200 μL of the solution from each group in step 4 was taken out and put into a 1.5 mL test tube (Eppendorf). Goat F(ab')2 anti-human IgG-(Fab')2 (PE) (abcam, cat. no. ab98606) was diluted with PBS at a volume ratio of 1:100, and 200 μL was added to the solution of each group. At the same time, 5 μL of CD16 monoclonal antibody (eBioscience) was added to each group. TM.17-0168-42) and reacted at 4°C for 30 minutes. 800 μL PBS was added and centrifuged at 400g for 5 minutes at 4-8°C, and the supernatant was removed. The cells were washed and centrifuged twice with 1 mL PBS, and the supernatant was removed. 200 μL PBS was added to dissolve the cells, and finally flow cytometry (FACS) was performed. Repeat step 5 every 24 hours until 96 hours. Experimental results: CD16 in PBMCs was detected with goat F(ab')2 anti-human IgG-(Fab')2 (PE) + Antibody staining on NK cell membrane, and then flow cytometry (FACS) analysis of PE signal to obtain trastuzumab-bound CD16 at different time points + The extent of NK cells. Figure 25 shows linker-bound trastuzumab-CD16 + The degree of binding to the NK cell membrane at different times. As shown in Figure 25, the arithmetic mean signal of antibody staining at 0 hours is 2219. After 96 hours in a 37°C cell culture incubator, the arithmetic mean signal dropped by about 45% to 1261. This shows that the trastuzumab bound to the linker is bound to CD16. + The half-life of antibodies on the surface of NK cells is about 4 days. Example 14 [Test of viability of cells with trastuzumab linked to a linker] The following describes the steps of the linker-bound trastuzumab cell viability assay. Step 1: After mixing 15 mL of fresh blood with PBS at a ratio of 1:1, add 15 mL of Ficoll-Paque Plus / Premium to a 50 c.c. centrifuge tube, then slowly add the blood and PBS mixture, centrifuge at 600 g for 20 minutes and turn the speed down to 0. After centrifugation, remove the upper plasma, take the PBMC layer to a new 50 c.c. centrifuge tube, and add PBS to 40 mL. Next, centrifuge at 400 g for 5 minutes, remove the supernatant, and add PBS to 40 mL. Next, centrifuge at 400 g for 5 minutes, remove the supernatant, and finally add PBS, and adjust the cell concentration to 2x10 6 cells / mL for subsequent experiments. Step 2: [Preparation of control group and experimental group] The control group was a mixture formed by adding 1 mL of PBS and 1 mL of PBMC cell solution; the experimental group was 900 μL of PBS and 100 μL of 1 mg / mL of trastuzumab solution bound by a linker was added. The solution was irradiated with UV at a wavelength of 365 nm for 10 seconds each time, and then paused for 10 seconds, for a total of two times. Then, 1 mL of PBMC cell solution from step 1 was added to make a mixture with a final concentration of 50 μg / mL of trastuzumab bound by a linker. Then, the mixture of the control group and the experimental group was allowed to stand at 4°C for 10 minutes. Step 3: The mixed solution in step 2 was centrifuged at 400g for 5 minutes at 4-8°C, and the supernatant was removed. The cells were then washed and centrifuged twice with 5 mL PBS, and finally the cells were lysed with cell culture medium (RPMI / 10% FBS). The cell concentration was adjusted to 1x10 6 cells / mL for subsequent experiments. Step 4: The linker-bound trastuzumab-PBMC cells and PBMC cells were seeded into a 96-well plate with a final volume of 200 μL / well. Then, each group of 6 wells was placed in a 37°C cell culture incubator and supplemented with 50 μL of cell culture medium every 24 hours. Step 5: Every 24 hours, 200 μL of the cell solution from step 4 was taken out and placed in a 1.5 mL test tube (Eppendorf). 5 μL of CD16 monoclonal antibody (eBioscience TM .17-0168-42) and reacted at 4°C for 30 minutes. Then, the two groups of cells were mixed with 100 μL / sample of Annexin V / PI solution and reacted at room temperature in the dark for 5 minutes, and then the Annexin V- / PI-cell population was analyzed by flow cytometry (FACS). Experimental results: First select CD16 in PBMC + NK cell population, and then analyze the Annexin V / PI staining cell ratio as a cell survival rate analysis. Figure 26 shows linker-bound trastuzumab bound to CD16 + The results of NK cell viability after 96 hours. As shown in Figure 26, between 0 hours and 96 hours, the linker-bound trastuzumab CD16 + The survival rate of NK cells was greater than 95%, which was no different from the PBMC control group. Therefore, it can be seen that the linker-bound trastuzumab bound to PBMC cells does not affect CD16 + The survival of NK cells' immune cells is affected. Example 15 [Connector chemical formula α allows rituximab to bind to cells] The following illustrates the steps by which the linker chemical formula α can bind different antibodies (rituximab) to cells: Step 1: 1 mL of 10 mg / mL MabThera commercially available antibody (Roche, rituximab) was placed in each Ultracentrifugal filter, add 13 mL of PBS, and centrifuge at 2500 g for 30 minutes at 4-8°C to remove The waste liquid below the ultracentrifugal filter was removed. 8 mL of PBS was added to the top and centrifuged at 2500 g for 30 minutes at 4-8°C. Next, the absorbance at 280 nm (OD280) was measured to calculate the concentration, and finally the antibody concentration was adjusted to 2 mg / mL with PBS for subsequent use. Step 2: Take 2.25 mg of the connector chemical formula α of Example 1 and mix it with 590 μL of DMSO solvent to prepare 10 mM linker solution. Step 3: 3 mL of rituximab prepared in step 1 was taken and 20.69 μL of the 10 mM linker solution prepared in step 2 was added and mixed, and reacted at room temperature for 30 minutes to produce linker-bound rituximab. Step 4: Place the linker-bound rituximab solution into Ultracentrifugal filter, add 11 mL PBS, and centrifuge at 2500 g for 30 min at 4-8°C to remove Add 6 mL of PBS to the top of the ultracentrifuge filter and centrifuge at 2500 g for 30 minutes at 4-8°C to remove the waste liquid. The waste liquid below the ultracentrifugal filter. Then, the absorbance at 280 nm (OD280) was measured to calculate the concentration, and the antibody concentration was adjusted to 5 mg / mL with PBS, and 62.5% glycerol was mixed with a volume of 1 (antibody): 4 (glycerol) and stored at -20°C, so that the final antibody concentration was 1 mg / mL for subsequent use. Step 5: Transfer 1 mL of frozen human NK cells (TCI GENE; Lot. no. 20211014) and 10 mL of PBS to a 15 mL centrifuge tube, centrifuge at 400 g for 5 minutes to wash, replace with 10 mL of NK culture medium (RPMI medium, 5% EG, 500 IU / mL rhIL-2) and transfer to a 10 cm cell culture dish for culture. After one day of culture at 37°C and 5% CO2, remove the washing and replacement buffer using the following method (A) or (B): (A) NK cells were transferred to a 15 mL centrifuge tube and centrifuged at 400 g at 4-8°C for 5 minutes. The supernatant was removed and the tube was washed with 10 mL PBS and centrifuged twice. Finally, NK cells were re-lysed with PBS and the concentration of NK cells was adjusted to 2 x 10 6 cells / mL. (B) NK cells were transferred to a 50 mL centrifuge tube and centrifuged at 400 g at 4-8°C for 5 minutes. The supernatant was removed and the tube was washed with 50 mL PBS and centrifuged once. Finally, NK cells were re-lysed with PBS and the concentration of NK cells was adjusted to 2 x 10 6 cells / mL. Finally, divide the solution into 3 tubes with 1 mL in each tube and label them as control group, comparison group and experimental group respectively. Step 6: [Preparation of control group, control group and experimental group] The control group was a mixture of 1 mL of PBS and 1 mL of NK cell solution; the control group was 900 μL of PBS and 100 μL of 1 mg / mL rituximab solution; the experimental group was 900 μL of PBS and 100 μL of 1 mg / mL linker-bound rituximab solution. Then, the mixture was mixed with 1 mL of NK cell solution in step 5 at a volume ratio of 1:1. The final concentration of Tuximab was 50 μg / mL, and the final concentration of NK cells was 1x10 6 Then, UV with a wavelength of 365 nm was set to 400 mJ / cm 2 The solution was irradiated uniformly, and the mixed solution of the control group, the control group, and the experimental group was allowed to stand at 2-8°C for 10 minutes. Step 7: Divide the mixture from step 6 into the following two groups for subsequent experiments: (A) For small-scale cell experiments: Transfer the mixture from step 2 to a 15 mL centrifuge tube and add an equal volume of PBS / 1% HSA solution. Centrifuge at 400 g for 5 minutes at 4-8°C, remove the supernatant, wash and centrifuge twice with 10 mL PBS / 1% HSA, and dissolve the NK cells according to the solution required for the experiment, and adjust the NK cell concentration to 2 x 10 6 cells / mL. (B) For large-scale animal testing: Transfer the mixture from step 2 to a 50 mL centrifuge tube and add an equal volume of PBS / 1% HSA solution. Centrifuge at 400 g at 4-8°C for 5 minutes. Remove the supernatant and wash once with 50 mL PBS / 1% HSA. Centrifuge once to obtain NK cells according to the experimental requirements and adjust the NK cell concentration to 2 x 10 6 cells / mL. Step 8: Take out 200 μL of each solution in step 7 into a 1.5 mL test tube (Eppendorf), dilute goat F(ab')2 anti-human IgG-(Fab')2(PE) (abcam, cat. no. ab98606) with PBS at a volume ratio of 1:100, take 200 μL and add it to the solution of each group in step 6, and then react at 4°C for 30 minutes. Then, add 800 μL PBS and centrifuge at 400g for 5 minutes at 4-8°C, remove the supernatant, and then centrifuge and wash twice with 1 mL PBS and remove the supernatant. Finally, add 200 μL PBS to each group to dissolve the cells and analyze them by flow cytometry (FACS). Experimental results: The antibody on the NK cell membrane was stained with goat F(ab')2 anti-human IgG-(Fab')2 (PE), and the PE signal of the NK cells was analyzed by flow cytometry (FACS) to obtain the strength of antibody binding to NK cells. Figure 27 shows the results of the linker-bound rituximab binding to NK cells. As shown in Figure 27, the linker-bound rituximab in the experimental group successfully bound to the surface of NK cells. FIG28 shows the binding ability of rituximab bound by a linker to NK cells. As shown in FIG28, compared with the rituximab in the control group, the rituximab bound by the linker (chemical formula α) in the experimental group has a better binding ability to NK cells. Therefore, the experiment proves that the strategy of binding antibodies to cells with linkers can be extended to other antibodies besides trastuzumab. Example 16 [Connector Chemical Formula α enables Atezolizumab to bind to cells] The following illustrates the steps by which the linker chemical formula α can bind different antibodies (atezolizumab) to cells: Step 1: 0.5 mL of 60 mg / mL Tecentriq commercially available antibody (Roche, Atezolizumab) was placed into each Ultracentrifugal filter, add 13 mL of PBS, and centrifuge at 2500 g for 30 minutes at 4-8°C to remove The waste liquid below the ultracentrifugal filter was removed. 8 mL of PBS was added to the top and centrifuged at 2500 g for 30 minutes at 4-8°C. Next, the absorbance at 280 nm (OD280) was measured to calculate the concentration, and finally the antibody concentration was adjusted to 2 mg / mL with PBS for subsequent use. Step 2: 2.25 mg of the connector chemical formula α of Example 1 was mixed with 590 μL of DMSO solvent to prepare a 10 mM connector solution. Step 3: 4 mL of the atezolizumab prepared in step 1 was added to 27.58 μL of the 10 mM linker solution prepared in step 2, and the mixture was reacted at room temperature for 30 minutes to produce the linker-bound atezolizumab. Step 4: Place the connector-bonded Liat beads solution into Ultracentrifugal filter, add 11 mL PBS, and centrifuge at 2500 g for 30 min at 4-8°C to remove Add 6 mL of PBS to the top of the ultracentrifuge filter and centrifuge at 2500 g for 30 minutes at 4-8°C to remove the waste liquid. The waste liquid below the ultracentrifugal filter was then filtered. Next, the absorbance at 280 nm (OD280) was measured to calculate the concentration, and the antibody concentration was adjusted to 5 mg / mL with PBS, and 62.5% glycerol was mixed at a volume of 1 (antibody): 4 (glycerol) and stored at -20°C, so that the final antibody concentration was 1 mg / mL for subsequent use. Step 5: Transfer 1 mL of frozen human NK cells (TCI GENE; Lot. no. 20211014) and 10 mL of PBS to a 15 mL centrifuge tube, centrifuge at 400 g for 5 minutes to wash, replace with 10 mL of NK culture medium (RPMI medium, 5% EG, 500 IU / mL rhIL-2) and transfer to a 10 cm cell culture dish for culture. After one day of culture at 37°C and 5% CO2, remove the washing and replacement buffer using the following method (A) or (B): (A) NK cells were transferred to a 15 mL centrifuge tube and centrifuged at 400 g at 4-8 °C for 5 minutes. The supernatant was removed and the cells were washed with 10 mL PBS and centrifuged twice. Finally, NK cells were re-lysed with PBS and lysed with PBS. Adjust the NK cell concentration to 2 x 10 6 cells / mL. (B) NK cells were transferred to a 50 mL centrifuge tube and centrifuged at 400 g at 4-8°C for 5 minutes. The supernatant was removed and the tube was washed with 50 mL PBS and centrifuged once. Finally, NK cells were re-lysed with PBS and the concentration of NK cells was adjusted to 2 x 10 6 cells / mL. Finally, divide the solution into 3 tubes with 1 mL in each tube and label them as control group, comparison group and experimental group respectively. Step 6: [Preparation of control group, control group and experimental group] The control group was a mixture of 1 mL of PBS and 1 mL of NK cell solution; the control group was 900 μL of PBS and 100 μL of 1 mg / mL Atezolizumab solution; the experimental group was 900 μL of PBS and 100 μL of 1 mg / mL linker-bound Atezolizumab solution. Then, the mixture was mixed with 1 mL of NK cell solution in step 5 at a volume ratio of 1:1 to make the final concentration of Atezolizumab 50 μg / mL and the final concentration of NK cells 1x10 6 Then, UV with a wavelength of 365 nm was set to 400 mJ / cm 2 The solution was irradiated uniformly, and the mixed solution of the control group, the control group, and the experimental group was allowed to stand at 2-8°C for 10 minutes. Step 7: Divide the mixture from step 6 into the following two groups for subsequent experiments: (A) For small-scale cell experiments: Transfer the mixture from step 2 to a 15 mL centrifuge tube and add an equal volume of PBS / 1% HSA solution. Centrifuge at 400 g for 5 minutes at 4-8°C, remove the supernatant, wash and centrifuge twice with 10 mL PBS / 1% HSA, and dissolve the NK cells according to the solution required for the experiment, and adjust the NK cell concentration to 2 x 10 6 cells / mL. (B) For large-scale animal testing: Transfer the mixture from step 2 to a 50 mL centrifuge tube and add an equal volume of PBS / 1% HSA solution. Centrifuge at 400 g at 4-8°C for 5 minutes. Remove the supernatant and wash once with 50 mL PBS / 1% HSA. Centrifuge once to obtain NK cells according to the experimental requirements and adjust the NK cell concentration to 2 x 10 6 cells / mL. Step 8: Take out 200 μL of each solution in step 7 into a 1.5 mL test tube (Eppendorf), dilute goat F(ab')2 anti-human IgG-(Fab')2(PE) (abcam, cat.no.ab98606) with PBS at a volume ratio of 1:100, take 200 μL and add it to the solution of each group in step 6, and then react at 4°C for 30 minutes. Next, add 800 μL PBS and centrifuge at 400g for 5 minutes at 4-8°C, remove the supernatant, and then centrifuge and wash twice with 1 mL PBS and remove the supernatant. Finally, add 200 μL PBS to each group to dissolve again. The cells were analyzed by flow cytometry (FACS). Experimental results: The antibody on the NK cell membrane was stained with goat F(ab')2 anti-human IgG-(Fab')2 (PE), and the PE signal of the NK cells was analyzed by flow cytometry (FACS) to obtain the strength of antibody binding to NK cells. Figure 29 shows the results of the linker-bound Atezolizumab binding to NK cells. As shown in Figure 29, the linker-bound Atezolizumab in the experimental group successfully bound to the surface of NK cells. FIG30 shows the binding ability of the linker-bound atezolizumab to NK cells. As shown in FIG30 , compared with the atezolizumab in the control group, the atezolizumab bound to the linker (chemical formula α) in the experimental group has a better binding ability to NK cells. Therefore, the experiment proves that the strategy of using a linker to bind antibodies to cells can be extended to other antibodies besides trastuzumab. Example 17 [Results of rituximab-bound PBMC cytotoxicity test] The following describes the steps of the rituximab-bound PBMC cytotoxicity assay: Step 1: Human Burkitt's lymphoma cells (Daudi cells) were cultured in a T75 culture flask with 15 mL of cell culture medium (90% RPMI 1640 medium with 2 mM L-glutamine, adjusted to contain 1.5 g / L sodium bicarbonate, 4.5 g / L gl glucose, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and 1.0 mM sodium pyruvate + 10% FBS) at 37°C and 5% CO2 for three days. The Daudi cells were transferred to a 50 mL centrifuge tube and centrifuged at 400 g for 5 minutes at 4-8°C to remove the supernatant, and then washed twice by centrifugation with PBS. Finally, the Daudi cells were re-dissolved with PBS to a cell concentration of 5x10 6 -1x10 7 cells / mL. Step 2: 2 mL of Daudi cells and 2 mL of 1 μM Deep Red solution were mixed in a 1:1 volume ratio to a total of 4 mL. After reacting at room temperature in the dark for 10 minutes, the cells were washed twice by centrifugation with PBS. Finally, the Daudi cells were re-dissolved with PBS to adjust the cell concentration to 1x10 5 cells / mL. Step 3: According to step 1 of Example 12, 2x10 6 cells / mL of PBMC cell solution. Step 4: [Preparation of control group, control group and experimental group] The control group was a mixture formed by adding 1 mL of PBS and 1 mL of PBMC cell solution; the control group was 900 μL of PBS and 100 μL of 1 mg / mL rituximab solution was added; the experimental group was 900 μL of PBS and 100 μL of 1 mg / mL rituximab solution with a linker chemical formula α was added. The solution was irradiated with UV at a wavelength of 365 nm for 10 seconds each time, and then paused for 10 seconds, for a total of two times, and then 1 mL of PBMC cell solution in step 3 was added to make a mixture with a final concentration of 50 μg / mL of rituximab antibody and a final concentration of 50 μg / mL of rituximab with a linker chemical formula α. Then, the mixture of the control group, the control group and the experimental group was allowed to stand at 4°C for 10 minutes. Step 5: The mixture in step 4 was centrifuged at 400 g at 4-8 °C for 5 minutes. The supernatant was removed and the cells were washed and centrifuged twice with 10 mL PBS. Finally, the cells were re-lysed with Daudi cell culture medium and the cell concentration was adjusted to 1x10 6 cells / mL for subsequent experiments. Step 6: PBMC cells and CellTracker were collected from the experimental group, control group and control group. TM Deep Red dye-stained Daudi cells were mixed in a 96-well plate at a ratio of 1:1, 5:1 and 10:1 to a final volume of 200 μL and reacted at 37°C for 4 hours. Step 7: 200 μL of the cytotoxic cells that had reacted for 4 hours were taken out and mixed with 100 μL of Annexin V / PI solution. After reacting for 5 minutes at room temperature in the dark, Deep Red was analyzed by flow cytometry (FACS). + / Annexin V + / PI + Cell populations. Experimental results: Select Deep Red first + Daudi cell population, and then analyze its Annexin V + / PI + The cell ratio of Daudi cells, excluding Daudi-474 spontaneous death (Annexin V + / PI + ) is used as a comparison of the NK cell cytotoxicity (specific lysis) effect. Figure 31 shows the results of the cytotoxicity test of rituximab-bound PBMC. As shown in Figure 31, compared with the PBMC of the control group and the rituximab+PBMC of the control group, the PBMC cells of the experimental group with the linker-bound antibody (chemical formula αPBMC) have a better cytotoxic effect, which is 12.67% and 26.06% at the E / T ratio (effector to target cell ratio) of 5:1 and 10:1, respectively, and the cytotoxic effect increases with the increase of the PBMC cell ratio. Example 18 [Linker-bound trastuzumab-NK cells in breast cancer xenograft model (xenograft model) efficacy] The following describes the steps for linker-conjugated trastuzumab-NK cells in breast cancer xenografts. Step 1: The efficacy of linker-bound trastuzumab was evaluated in NOD-SCID mice using a subcutaneous BT-474 (cultured at passages p3-p6 after thawing) xenograft tumor model. Three groups consisting of vehicle control (n=8), control (n=7), and experimental group (n=7) were used, which were saline containing 1% human serum albumin (HAS), NK cells, and linker-bound trastuzumab-NK, respectively. The BT-474 xenograft tumor model was established in NOD-SCID mice (female and nulliparous, non-pregnant), and estradiol pellets were implanted in the back of each mouse. 7 days before administration, 2.5x 10 6 BT-474 cells / mouse (BT-474 cells suspended in a 1:1 mixture of 0.1 mL 1x DPBS:0.1 mL Matrigel). At the start of the study, animals were 7 weeks old and body weight variation should not exceed ±20% of the mean body weight of each sex. Step 2: According to Example 4, trastuzumab with a linker chemical formula α was prepared. Step 3: 6 mL of frozen human NK cells (TCI GENE; Lot. no. 20211014) and 18 mL of PBS (containing 1% HSA) were transferred to a 50 mL centrifuge tube and centrifuged at 400 g for 5 minutes to remove the supernatant. Next, the supernatant was removed after centrifugation with PBS (containing 1% HSA) and replaced with 40 mL of NK culture medium (RPMI medium, 5% EG, 500 IU / mL rhIL-2) to adjust the NK cell concentration to 5x10 5 cells / mL, and transfer 20mL of cell solution to a T75 culture flask for culture. After two days of culture at 37°C and 5% CO2, the NK cells were transferred to a 50mL centrifuge tube, and the T75 culture flask was rinsed with 5mL PBS and transferred to a 50mL centrifuge tube. The supernatant was removed after centrifugation at 400g for 9 minutes at 4-8°C, and then washed twice by centrifugation with PBS. Finally, the NK cells were re-dissolved with PBS and divided into two groups, which were labeled as the control group and the experimental group. The concentration of NK cells in the experimental group was adjusted to 2x10 6 cells / mL. Step 4: [Preparation of control group and experimental group] The NK cell solution of the control group was added with 1% HSA in saline, centrifuged at 400g for 5 minutes at 4-8°C, and the supernatant was removed. The NK cells were then re-dissolved with 1% HSA in saline and the concentration of the NK cells of the control group was adjusted to 1x10 7cells / mL; take 27.9 ml of PBS and add 2.1 mL of 1 mg / mL linker-bound trastuzumab solution. The cell solution was evenly irradiated for 10 seconds and paused for 10 seconds, twice in total, and then the experimental group NK cell solution in step 2 was added to make it a mixed solution with a final concentration of 35 μg / mL of trastuzumab bonded with the connector chemical formula α, and the mixed solution of the experimental group was allowed to stand at 4°C for 15 minutes. Step 5: The mixture in step 4 was centrifuged at 400 g for 5 minutes at 4-8°C, and the supernatant was removed. The cells were washed with PBS and centrifuged twice. Finally, the cells were lysed with 1% HSA in physiological saline and the cell concentration was adjusted to 1x10 7 cells / mL. And confirm that the binding rate of trastuzumab linked with the linker chemical formula α to NK cells is ≥ 70% and the NK purity (CD3 + CD56 + )≧50%. Step 6: The drug was administered intraperitoneally at 0.5 mL / mouse on days 1, 4, 7, 11, and 14, for a total of 5 times. Mice with incomplete dosing and those with non-solid tumors identified after autopsy were excluded from the results of this study. The above data analysis data are as follows: mean ± SEM; one-way ANOVA by t-test (Cochran-Cox-test); *p<0.05. The tumor growth inhibition (TGI) formula is: (mean tumor size of the vehicle control group - individual tumor size) / (mean tumor size of the vehicle control group) x 100%. Experimental results: Figure 32 shows the results of tumor volume measurement. As shown in Figure 32, from the 18th day to the 35th day after administration, the experimental group (trastuzumab NK cells linked to the linker, n = 6) inhibited tumor growth and caused the tumor volume to begin to shrink. On the 35th day, the tumor volumes of the vector control group, NK cell control group and experimental group were 276.1±51.1mm 3 、175.1±40.9mm 3 118±15.2mm 3 , it can be seen that the tumor volume in the experimental group was significantly smaller. FIG33 shows the results of the tumor growth inhibition rate (TGI%) analysis. As shown in FIG33, compared with the vehicle control group (1% HSA in saline, n = 6), the experimental group (linker-bound trastuzumab NK cells, n = 6) has a statistically significant tumor growth inhibition rate (57.3 ± 5.5%, p < 0.05), while the control group (NK cells, n = 6) has no statistically significant tumor growth inhibition rate (36.6 ± 14.8%). It can be seen that the linker-bound trastuzumab NK cells significantly enhance the anti-tumor effect, and also show its potential to be converted into human clinical trials and linker-bound antibodies for application in the field of cell therapy. Example 19 [Analysis of the cytotoxicity of linker-bound trastuzumab-NK cells to N87 gastric cancer cells] The following describes the steps for comparing the cytotoxicity of linker-bound trastuzumab-NK cells against N87 gastric cancer cells. Step 1: N87 gastric cancer cells were cultured in 10 cm cell culture dishes with 10 mL of cell culture medium (IMDM / 10% FBS / 30 ng / mL EGF) for three days at 37°C and 5% CO2. The cell culture medium was removed and washed with 10 mL of PBS, followed by the addition of 1 mL of CTS TM TrypLE TM Select enzyme and react at 37°C, 5% CO2 for 5 minutes. Then, add 10mL cell culture medium to harvest the cells, transfer them to a 15mL centrifuge tube, and centrifuge at 400g for 5 minutes at 4-8°C. After removing the supernatant, wash with PBS and centrifuge twice. Finally, dissolve the N87 gastric cancer cells with PBS and adjust the cell concentration to 5x10 6 -1x10 7 cells / mL. Step 2: Add 20 μL DMSO solvent to the Deep Red reagent tube, take out 5 μL Deep Red solution and add it to 1 μM CellTracker prepared in 5 mL PBS. TM Deep Red stain (Invitrogen TM , C34565) solution and store in the dark. 2 mL of N87 gastric cancer cells and 2 mL of 1 μM Deep Red solution were mixed in a 1:1 volume ratio to a total of 4 mL, and then reacted in the dark at room temperature for 10 minutes. Step 3: Take 10mL of cell culture medium (IMDM / 10% FBS / 30ng / mL EGF) and centrifuge twice to wash H2170 cells with Deep Red dye, 400g 4-8℃, 5 minutes. Adjust the cell concentration of Deep Red-stained N87 gastric cancer cells to 1x105 cells / mL. Step 4: The NK cells of the experimental group, control group and control group of Example 6 were compared with CellTracker TM H2170 cells were stained with Deep Red dye and mixed at a ratio of 1:1, 5:1 and 10:1 to a final volume of 200 μL, placed in a 96-well flat-bottom plate, and reacted at 37°C for 4 hours. Step 5: Prepare 100 μL of Annexin V / PI solution (98.5 μL 1X binding buffer plus 1 μL Annexin V and 0.5 μL PI). Take out 200 μL of the cytotoxic cells that have been reacting for 4 hours and mix them with 100 μL of Annexin V / PI solution. After reacting for 5 minutes at room temperature in the dark, analyze Deep Red by flow cytometry (FACS). + / Annexin V + / PI + Cell populations. Experimental results: Figure 34 shows the analysis results of the cytotoxicity of trastuzumab-NK cells to N87 gastric cancer cells. As shown in Figure 34, compared with the NK of the control group and the NK+trastuzumab of the control group, the experimental group The linker-trastuzumab-bound NK cells (chemical formula δ-NK) have a good gastric cancer (N87) cell cytotoxicity effect, with E / T ratios of 1:1 and 5:1 being 41%+5.2% and 71.6%+9.4%, respectively, and the cytotoxicity effect increases with the increase of the NK cell ratio. Example 20 [Analysis of the cytotoxicity of linker-bound trastuzumab-NK cells to H2170 lung cancer cells] The following describes the steps for comparing the cytotoxicity of linker-bound trastuzumab-NK cells against H2170 lung cancer cells. Step 1: H2170 lung cancer cells were cultured in 10 cm cell culture dishes with 10 mL of cell culture medium (IMDM / 10% FBS / 30 ng / mL EGF) for three days at 37°C and 5% CO2. The cell culture medium was removed and washed with 10 mL of PBS, followed by the addition of 1 mL of CTS. TM TrypLE TM Select enzyme and react at 37°C, 5% CO2 for 5 minutes. Then, add 10mL cell culture medium to harvest the cells, transfer them to a 15mL centrifuge tube, and centrifuge at 400g for 5 minutes at 4-8°C. After removing the supernatant, wash with PBS and centrifuge twice. Finally, re-dissolve the H2170 lung cancer cells with PBS and adjust the cell concentration to 5x106 -1x10 7 cells / mL. Step 2: Add 20 μL DMSO solvent to the Deep Red reagent tube, take out 5 μL Deep Red solution and add it to 1 μM CellTracker prepared in 5 mL PBS. TM Deep Red stain (Invitrogen TM , C34565) solution and store in the dark. 2 mL of H2170 lung cancer cells and 2 mL of 1 μM Deep Red solution were mixed in a 1:1 volume ratio to a total of 4 mL, and then reacted in the dark at room temperature for 10 minutes. Step 3: Take 10mL of cell culture medium (IMDM / 10% FBS / 30ng / mL EGF) and centrifuge twice to wash H2170 lung cancer cells with Deep Red dye, 400g 4-8℃, 5 minutes. Adjust the cell concentration of Deep Red stained H2170 lung cancer cells to 1x10 5 cells / mL. Step 4: The NK cells of the experimental group, control group and control group of Example 6 were compared with CellTracker TM H2170 lung cancer cells were stained with Deep Red dye and mixed in a final volume of 200 μL at a ratio of 1:1, 5:1 and 10:1, respectively, and then placed in a 96-well flat-bottom plate and reacted at 37°C for 4 hours. Step 5: Prepare 100 μL of Annexin V / PI solution (98.5 μL 1X binding buffer plus 1 μL Annexin V and 0.5 μL PI). Take out 200 μL of the cytotoxic cells that have been reacting for 4 hours and mix it with 100 μL The Annexin V / PI solution was mixed and reacted at room temperature in the dark for 5 minutes. Deep Red + / Annexin V + / PI + Cell populations. Experimental results: Figure 35 shows the analysis results of the cytotoxicity of H2170 lung cancer cells by the linker-bound trastuzumab-NK cells. As shown in Figure 35, compared with the NK in the control group and the NK+He cancer cell in the control group, the linker-trastuzumab-bound NK cells (chemical formula δ-NK) in the experimental group have a better cytotoxicity to lung cancer (H2170) cells, and the E / T ratios of 1:1 and 5:1 are 58.3%+6.2% and 79.9%+4.3%, respectively, and the cytotoxicity increases with the increase of the NK cell ratio. Example 21 [Analysis of the Effect of UV Irradiation Energy on the Binding Degree of Trastuzumab with Different Hydrocarbon Chain Linkers to NK Cells] The following is a step to compare the degree of binding of trastuzumab with different hydrocarbon linkers to NK cells under different UV365nm irradiation energies: Step 1: Take four tubes of 5 mL (2 mg / mL) trastuzumab antibody (Roche, trastuzumab), add 67.55 μL of 10 mM linker chemical formula α solution, 67.55 μL of 10 mM linker chemical formula δ solution, and 101.3 μL of 10 mM NHS-diazirine solution and mix. Then, react at room temperature for 30 minutes or at 2-8°C for 3 hours to produce chemical formula α-T solution, chemical formula δ-T solution, and diazirine-T solution. Step 2: The trastuzumab solutions with different linkers were placed in Ultracentrifugal filter, add 11 mL of PBS, and centrifuge at 2500 g for 30 minutes at 4-8°C. Remove the waste liquid below the ultracentrifugal filter, add 6 mL of PBS above, and centrifuge at 2500 g for 30 minutes at 4-8°C. The waste liquid below the ultracentrifugal filter was then measured for concentration by OD280 absorbance. The antibody concentration was adjusted to greater than 5 mg / mL with PBS and mixed with 62.5% glycerol at a volume of 1 (antibody): 4 (glycerol) and stored at -20°C. Step 3: [Prepare control group, control group and experimental group] 1 mL of frozen human NK cells (TCI GENE; Lot. no. 20210816) and 10 mL of PBS were transferred to a 15 mL centrifuge tube and centrifuged at 400 g for 5 minutes for washing. The NK cell concentration was adjusted to 5 x 10 with NK culture medium (RPMI medium, 5% EliteGro, 500 IU / mL rhIL-2). 5Cells / mL transferred to T75 After one day of culture at 37°C and 5% CO2, the NK cells were transferred to a 50 mL centrifuge tube and centrifuged at 400 g for 10 minutes at 4-8°C. The supernatant was removed and the cells were washed and centrifuged twice with 50 mL PBS. Finally, the NK cells were re-dissolved with PBS and the concentration of NK cells was adjusted to 2x10 6 Cells / mL. Dispense into 0.3 mL tubes and mix with trastuzumab (60 μg / mL) solution, diazepam-T solution (60 μg / mL), chemical formula α-T solution (60 μg / mL), and chemical formula δ-T solution (60 μg / mL), respectively, and label as control group (no UV irradiation), control group (trastuzumab and diazepam-T), and experimental group (chemical formula α-T and chemical formula δ-T). Expose the solutions to 100, 200, 300, 400, and 500 mJ / cm with UV at a wavelength of 365 nm. 2 Then, the mixed solution of the control group, the control group and the experimental group was placed at 2-8°C for 10 minutes, and then a blocking solution (1% human serum albumin / RPMI culture medium) was added. Step 4: The mixture in step 3 was centrifuged at 400g for 5 minutes at 4-8°C, and the supernatant was removed. The cells were washed and centrifuged twice with 10 mL PBS, and finally the cells were dissolved with PBS and the cell concentration was adjusted to 5x10 5 cells / mL for subsequent experiments. Step 5: Take out 200 μL of each solution from step 4 and transfer it to a 1.5 mL test tube (Eppendorf). Dilute Goat F(ab')2 Anti-Human IgG-(Fab')2(PE)(abcam, cat. no. ab98606) and CD16 Monoclonal Antibody(eBioscience) in a volume ratio of 1:100 and 1:200 respectively. TM .17-0168-42), 200 μL was added to the solution of each group, and the cells were placed at 4°C for reaction for 15-30 minutes. 1000 μL PBS was added, and the cells were centrifuged at 400g for 5 minutes at 4-8°C, and the supernatant was removed. The cells were washed and centrifuged twice with 1 mL PBS, and the supernatant was removed. 200 μL PBS was added to each group to dissolve the cells, and the cells were analyzed by flow cytometry (FACS). Finally, Goat F(ab')2 Anti-Human IgG-(Fab')2(PE) and CD16 monoclonal antibody were used to stain the NK cell membrane, and then flow cytometry (FACS) was used to analyze CD16 +The PE signal of NK cells is used to obtain the strength of trastuzumab binding to NK cells. Experimental results: FIG36 shows the analysis results of different UV irradiation energies for the degree of binding of trastuzumab with different linkers to NK cells. As shown in FIG36, after irradiation with UV365nm, compared with the control group of trastuzumab NK and the commercially available light-sensitive molecule control group of diazolin-T NK, the chemical formula α-T NK and chemical formula δ-T NK in the experimental group successfully bound to the surface of NK cells, wherein the chemical formula α-T, chemical formula δ-T and NK cells were exposed to UV365nm at 200-400mJ / cm 2 Bonds with higher energy intensity Degree of knot. Example 22 [Analysis of the binding degree of trastuzumab bound to NK cells by different hydrocarbon chain linkers after UV irradiation reaction time] The following illustrates the effects of different hydrocarbon linker-bound trastuzumab on the 2 Steps to compare bonding degree at different reaction times at low temperature when irradiated with UV365nm: Step 1: Take four tubes of 5 mL (2 mg / mL) trastuzumab antibody (Roche, trastuzumab), add 67.55 μL of 10 mM linker chemical formula α solution, 67.55 μL of 10 mM linker chemical formula δ solution, and 101.3 μL of 10 mM NHS-diazirine solution and mix. Then, react at room temperature for 30 minutes or at 2-8°C for 3 hours to produce chemical formula α-T solution, chemical formula δ-T solution, and diazirine-T solution. Step 2: The trastuzumab solutions with different linkers were placed in Ultracentrifugal filter, add 11 mL of PBS, and centrifuge at 2500 g for 30 minutes at 4-8°C. Remove the waste liquid below the ultracentrifugal filter, add 6 mL of PBS above, and centrifuge at 2500 g for 30 minutes at 4-8°C. The waste liquid below the ultracentrifugal filter was then measured for concentration by OD280 absorbance. The antibody concentration was adjusted to greater than 5 mg / mL with PBS and mixed with 62.5% glycerol at a volume of 1 (antibody): 4 (glycerol) and stored at -20°C. Step 3: [Prepare control group, control group and experimental group] 1 mL of frozen human NK cells (TCI GENE; Lot. no. 20210816) and 10 mL of PBS were transferred to a 15 mL centrifuge tube and centrifuged at 400 g for 5 minutes for washing. The NK cell concentration was adjusted to 5 x 10 with NK culture medium (RPMI medium, 5% EliteGro, 500 IU / mL rhIL-2). 5 Cells / mL were transferred to T75 culture flasks for culture. After one day of culture at 37°C and 5% CO2, NK cells were transferred to 50mL centrifuge tubes, centrifuged at 400g for 10 minutes at 4-8°C, and the supernatant was removed. The cells were then washed and centrifuged twice with 50mL PBS. Finally, NK cells were re-dissolved with PBS and the NK cell concentration was adjusted to 2x10 6 Cells / mL. Dispense into 0.3 mL tubes and mix with trastuzumab (60 μg / mL) solution, diazepam-T solution (60 μg / mL), chemical formula α-T solution (60 μg / mL), and chemical formula δ-T solution (60 μg / mL), respectively, and label them as control group (no hypothermic reaction), control group (trastuzumab and diazepam-T), and experimental group (chemical formula α-T and chemical formula δ-T). 2 , UV with wavelength of 365nm After the exposure solution, the mixed solutions of the control group, the control group and the experimental group were placed at 2-8°C for 1, 5, 10 and 15 minutes respectively, and then a blocking solution (1% human serum albumin / RPMI medium) was added. Step 4: The mixture in step 3 was centrifuged at 400g for 5 minutes at 4-8°C, and the supernatant was removed. The cells were washed and centrifuged twice with 10 mL PBS, and finally the cells were dissolved with PBS and the cell concentration was adjusted to 5x10 5 cells / mL for subsequent experiments. Step 5: Take out 200 μL of each solution from step 4 and transfer it to a 1.5 mL test tube (Eppendorf). Dilute Goat F(ab')2 Anti-Human IgG-(Fab')2(PE)(abcam, cat. no. ab98606) and CD16 Monoclonal Antibody(eBioscience) in a volume ratio of 1:100 and 1:200 respectively. TM.17-0168-42), 200 μL was added to the solution of each group, and the cells were placed at 4°C for reaction for 15-30 minutes. 1000 μL PBS was added, and the cells were centrifuged at 400g for 5 minutes at 4-8°C, and the supernatant was removed. The cells were washed and centrifuged twice with 1 mL PBS, and the supernatant was removed. 200 μL PBS was added to each group to dissolve the cells, and the cells were analyzed by flow cytometry (FACS). Finally, Goat F(ab')2 Anti-Human IgG-(Fab')2(PE) and CD16 monoclonal antibody were used to stain the NK cell membrane, and CD16 was analyzed by flow cytometry (FACS). + The PE signal of NK cells is used to obtain the strength of trastuzumab binding to NK cells. Experimental results: Figure 37 shows the analysis results of the degree of binding of trastuzumab with different linkers to NK cells at different reaction times after UV irradiation. As shown in Figure 37, after irradiation with UV365nm, compared with the trastuzumab NK in the control group and the diazolin-T NK in the commercially available light-sensitive molecule control group, the chemical formula α-T NK and chemical formula δ-T NK in the experimental group successfully bound to the surface of NK cells, among which the chemical formula α-T and chemical formula δ-T had a higher degree of binding with NK cells at low temperature for 5-15min. Example 23 [Analysis of the degree of NK cell binding and cytotoxicity of trastuzumab bound by different hydrocarbon chain linkers at different antibody concentrations] The following describes the steps for comparing the degree of NK binding and cytotoxicity of trastuzumab with different hydrocarbon chain linkers after UV irradiation at different antibody concentrations: Step 1: Take four tubes of 5 mL (2 mg / mL) of trastuzumab (Roche, trastuzumab), add 67.55 μL of 10 mM solution of the chemical formula α, 67.55 μL of 10 mM solution of the chemical formula δ, 101.3 μL of 10 mM NHS-Diazirine solution was mixed, and then reacted at room temperature for 30 minutes or at 2-8° C. for 3 hours to produce a chemical formula α-T solution, a chemical formula δ-T solution, and a diazirine-T solution. Step 2: The trastuzumab solutions with different linkers were placed in Ultracentrifugal filter, add 11 mL of PBS, and centrifuge at 2500 g for 30 minutes at 4-8°C. Remove the waste liquid below the ultracentrifugal filter, add 6 mL of PBS above, and centrifuge at 2500 g for 30 minutes at 4-8°C. The waste liquid below the ultracentrifugal filter was then measured for concentration by OD280 absorbance. The antibody concentration was adjusted to greater than 5 mg / mL with PBS and mixed with 62.5% glycerol at a volume of 1 (antibody): 4 (glycerol) and stored at -20°C. Step 3: [Prepare control group, control group and experimental group] 1 mL of frozen human NK cells (TCI GENE; Lot. no. 20210816) and 10 mL of PBS were transferred to a 15 mL centrifuge tube and centrifuged at 400 g for 5 minutes for washing. The NK cell concentration was adjusted to 5 x 10 with NK culture medium (RPMI medium, 5% EliteGro, 500 IU / mL rhIL-2). 5 Cells / mL were transferred to T75 culture flasks for culture. After one day of culture at 37°C and 5% CO2, NK cells were transferred to 50mL centrifuge tubes, centrifuged at 400g for 10 minutes at 4-8°C, and the supernatant was removed. The cells were then washed and centrifuged twice with 50mL PBS. Finally, NK cells were re-dissolved with PBS and the NK cell concentration was adjusted to 2x10 6 Cells / mL. Dispense into 0.3 mL tubes and mix with trastuzumab (60 μg / mL) solution, diazepam-T solution (60 μg / mL), chemical formula α-T solution (20, 40, 60 μg / mL), chemical formula δ-T solution (20, 40, 60 μg / mL), and label the control group (only NK), control group (trastuzumab and diazepam-T) and experimental group (chemical formula α-T and chemical formula δ-T) respectively. 2 After the solutions were exposed to UV at a wavelength of 365nm, the mixed solutions of the control group, the control group and the experimental group were placed at 2-8°C for 1, 5, 10 and 15 minutes respectively, and then blocking solution (1% human serum albumin / RPMI culture medium) was added. Step 4: The mixture in step 3 was centrifuged at 400g for 5 minutes at 4-8°C, and the supernatant was removed. The cells were washed and centrifuged twice with 10 mL PBS, and finally the cells were dissolved with PBS and the cell concentration was adjusted to 5x10 5 cells / mL for subsequent experiments. Step 5: Lung cancer cells NCIH2170 were cultured in 10 mL of cell culture medium (RPMI / 10% FBS) in a 10 cm cell culture dish at 37°C and 5% CO2 for three days. The cell medium was removed and washed with 10 mL of PBS, and 1 mL of CTS was added. TM TrypLE TM Select enzyme, react at 37℃, 5% CO2 for 5 minutes, add 10mL cell culture medium to harvest cells. Transfer to 15mL centrifuge tube, centrifuge at 400g for 5 minutes at 4-8℃, remove supernatant, wash with PBS and centrifuge twice. Finally, dissolve NCIH2170 cells with PBS and adjust the cell concentration to 5x10 6 -1x10 7 cells / mL. Step 6: Add 20 μL DMSO solvent to the Deep Red reagent tube. Take out 5 μL Deep Red solution and add it to 5 mL PBS to prepare 1 μM CellTracker TM Deep Red stain (Invitrogen TM , C34565) solution, store in dark. Mix 2 mL of breast cancer cell BT474 and 2 mL of 1 μM Deep Red solution in a 1:1 volume ratio, totaling 4 mL. Incubate at room temperature in dark for 10 minutes. Step 7: Wash the NCIH2170 cells stained with Deep Red twice by centrifugation in 10 mL of cell culture medium (RPMI / 10% FBS) at 400 g and 4-8°C for 5 minutes. Adjust the concentration of Deep Red stained breast cancer cell BT474 cells to 1x10 5 cells / mL. Step 8: Take the experimental group, control group and control group NK cells and CellTracker TM Deep Red dye-stained BT474 cells were mixed in a 96-well plate at a ratio of 5:1, and the final volume was 200 μL, and then incubated at 37°C for 5 hours. Step 9: Prepare 100 μL of Annexin V / PI solution (98.5 μL 1X Binding buffer plus 1 μL Annexin V and 0.5 μL PI). Take out 200 μL of the cytotoxic cells that have been reacting for 5 hours and mix it with 100 μL of Annexin V / PI solution. After reacting at room temperature in the dark for 5 minutes, analyze Deep Red by FACS. + / Annexin V + / PI+ Cell populations. Step 10: Take out 200 μL of each solution from step 4 and transfer it to a 1.5 mL test tube (Eppendorf). Dilute Goat F(ab')2 Anti-Human IgG-(Fab')2(PE)(abcam, cat. no. ab98606) and CD16 Monoclonal Antibody(eBioscience) in a volume ratio of 1:100 and 1:200 respectively. TM .17-0168-42), take 200μL and add it to the solution of each group, place it at 4℃ for reaction for 15-30 minutes. Add 1000μL PBS and centrifuge at 400g for 5 minutes at 4-8℃, remove the supernatant, wash it with 1mL PBS and centrifuge it twice, remove The supernatant was collected and 200 μL PBS was added to each group to dissolve the cells, and the cells were analyzed by flow cytometry (FACS). Finally, Goat F(ab')2 Anti-Human IgG-(Fab')2(PE) and CD16 monoclonal antibody were used to stain the NK cell membrane, and then flow cytometry (FACS) was used to analyze CD16 + The PE signal of NK cells is used to obtain the strength of trastuzumab binding to NK cells. Experimental results [Bonding rate analysis]: Figure 38 is a diagram showing the degree of binding of trastuzumab with different linkers to NK at different antibody concentrations. As shown in Figure 38, trastuzumab with different linkers reacted with NK at 10, 20, and 30 μg / mL, and after UV 365nm irradiation and reaction at low temperature, compared with the control group of trastuzumab NK and the commercially available light-sensitive molecule control group of diazolin-T NK, chemical formula α-T NK and chemical formula δ-T NK successfully bound to the surface of NK cells, among which chemical formula α-T and chemical formula δ-T had a higher binding ratio with NK cells at 10 μg / mL. Experimental results [Cytotoxicity analysis]: Select Deep Red first +NCI-H2170 cell population, control group / experimental group / control group dead cells (Annexin V and PI stained cells) and NCI-H2170 spontaneous dead cells (Annexin V and PI stained cells) subtracted, and then divided by the ratio of Annexin V- / PI-NCI-H2170 live cells, as a comparison of cytotoxic effects. Figure 39 is a graph showing the analysis of cytotoxic results of trastuzumab with different hydrocarbon chain linkers after UV irradiation. As shown in Figure 39, compared with the NK (45±6%) of the control group and the trastuzumab NK and diazepam-T NK (48±7%) of the control group, the 1-T and 4-T NK cells of the experimental group have better cytotoxic effects, among which the chemical formula 1-T NK (30μg / mL) cells of the experimental group have the best cytotoxic ability, which has a 69±5% cytotoxic ratio at a 5:1ET ratio, and the cytotoxic effect increases with the increase of the antibody concentration ratio. Several embodiments are summarized above so that those with common knowledge in the art to which the present invention belongs can more easily understand the concepts of the embodiments of the present invention. Those with common knowledge in the art to which the present invention belongs should understand that they can design or modify other processes and structures based on the embodiments of the present invention to achieve the same purposes and / or advantages as the embodiments introduced herein. Those with common knowledge in the art to which the present invention belongs should also understand that such equivalent processes and structures do not deviate from the spirit and scope of the present invention, and they can make various changes, substitutions and replacements without violating the spirit and scope of the present invention.

Claims

1. A target molecule-cell complex having formula (I): X-A1-L-A2-D Formula (I) in: X is a cell; A1 is a substituted or unsubstituted indazolone moiety; L is -O-(CH2) m -W-(CH2) n -, wherein m and n are each independently an integer between 0 and 10, and W is a single bond or -NHCO- or a substituted or unsubstituted 1-4 unit polyethylene glycol (PEG); A2 is -CONH- or -COS-; and D is a targeting moiety. 2 . The targeting molecule-cell complex according to claim 1 , wherein A1 is an indazolone group substituted with a methoxy group.

3. The target molecule-cell complex according to claim 2, which has a structure of formula (II) or (III): Wherein X, L, A2 and D are as defined in claim 1.

4. The target molecule-cell complex according to claim 1, wherein L is -O-(CH2) m+n -, and 3≦(m+n)≦9.

5. The target molecule-cell complex according to claim 1, wherein L is -O-(CH2) m -NHCO-(CH2) n -, and 3≦(m+n)≦9. The targeting molecule-cell complex according to claim 1 , wherein L is 1-4 units of substituted or unsubstituted polyethylene glycol. 7 . The targeting molecule-cell complex according to claim 1 , wherein the cell is a mesenchymal stem cell, a blood cell or a bacterial cell.

8. The targeting molecule-cell complex according to claim 7, wherein the mesenchymal stem cells include adipose-derived mesenchymal stem cells (ADMSCs), hematopoietic stem cells, bone marrow mesenchymal stem cells, umbilical cord mesenchymal stem cells and placental stem cells.

9. The targeting molecule-cell complex according to claim 7, wherein the blood cell comprises a platelet, a T cell, a natural killer cell, a dendritic cell, a macrophage, a granulocyte, or a combination thereof.

10. The target molecule-cell complex according to claim 1, wherein the target moiety is an antigen-binding molecule. 11 . The targeting molecule-cell complex according to claim 10 , wherein the targeting portion has an amine group (NH 2 group) or a sulfhydryl group (sulfhydryl group). 12 . The target molecule-cell complex according to claim 10 , wherein the target moiety is a small molecule, an aptamer, a peptide, an antibody or a combination thereof.

13. The target molecule-cell complex according to claim 11, wherein the antibody is a single chain variable fragment (scFv), a fragment antigen binding (Fab) fragment or a full-length antibody.

14. A method for preparing a target molecule-cell complex, comprising: A connector having the formula (IV) is provided: Wherein, L is -O-(CH2) m -W-(CH2) n -, wherein m and n are each independently an integer between 0 and 10, and W is a single bond or -NHCO- or a substituted or unsubstituted polyethylene glycol of 1 to 4 units; allowing the linker to react with a target molecule having an amine group to form a linker-target molecule complex, wherein the linker and the target molecule are bound to each other via an amide bond; and The linker-target molecule complex is irradiated with ultraviolet light to make the linker-target molecule complex after irradiation with ultraviolet light react with a cell, wherein the linker-target molecule complex and the cell form a target molecule-cell complex through an indazolone part.

15. The method for preparing a target molecule-cell complex according to claim 14, wherein the connector has a structure selected from the group consisting of the following compounds: as well as 16 . The method for preparing a target molecule-cell complex according to claim 14 , wherein the molar ratio of the target molecule to the linker used to form the linker-target molecule complex is 1:1 to 1:

15. 17 . The method for preparing a target molecule-cell complex according to claim 14 , wherein the step of irradiating the linker-target molecule complex with ultraviolet light is performed in a cycle of irradiating the linker-target molecule complex with ultraviolet light for 5 to 30 seconds and letting it stand for 1 to 30 seconds. 18 . The method for preparing a target molecule-cell complex according to claim 14 , wherein the cycle is performed 1 to 6 times.

19. The method for preparing a target molecule-cell complex according to claim 14, wherein the step of allowing the linker-target molecule complex irradiated with ultraviolet light to react with the cell is performed for at least 1 minute.

20. The method for preparing a target molecule-cell complex according to claim 14, wherein the step of irradiating the linker-target molecule complex with ultraviolet light comprises first mixing the linker-target molecule complex with the cell, and then irradiating the linker-target molecule complex and the cell simultaneously with ultraviolet light.

21. Use of the target molecule-cell complex according to claim 1 in preparing a drug for treating cancer.

22. Use of the target molecule-cell complex according to claim 1 in the preparation of a drug for promoting cell homing.

23. Use of the target molecule-cell complex according to claim 1 in the preparation of a drug for treating autoimmune diseases.

Images